<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Ophthalmol</journal-id><journal-id journal-id-type="iso-abbrev">Indian J Ophthalmol</journal-id><journal-id journal-id-type="publisher-id">IJO</journal-id><journal-id journal-id-type="publisher-id">Indian J Ophthalmol</journal-id><journal-title-group><journal-title>Indian Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="ppub">0301-4738</issn><issn pub-type="epub">1998-3689</issn><publisher><publisher-name>Wolters Kluwer - Medknow</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38389252</article-id><article-id pub-id-type="pmc">PMC467016</article-id>
<article-id pub-id-type="publisher-id">IJO-72-335</article-id><article-id pub-id-type="doi">10.4103/IJO.IJO_3204_23</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Molecular genetics of inherited normal tension glaucoma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pan</surname><given-names>Yang</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Iwata</surname><given-names>Takeshi</given-names></name><xref rid="aff1" ref-type="aff"/><xref rid="cor1" ref-type="corresp"/></contrib></contrib-group><aff id="aff1">National Institute of Sensory Organs, NHO Tokyo Medical Center, Japan</aff><author-notes><corresp id="cor1"><bold>Correspondence to:</bold> Prof. Takeshi Iwata, 2-5-1 Higashigaoka, Meguro-ku, Tokyo 152-8902, Japan. E-mail: <email xlink:href="takeshi.iwata@kankakuki.jp">takeshi.iwata@kankakuki.jp</email></corresp></author-notes><!--Fake ppub date generated by PMC from publisher
					pub-date/@pub-type='epub-ppub'--><pub-date pub-type="ppub"><month>5</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>23</day><month>2</month><year>2024</year></pub-date><volume>72</volume><issue>Suppl 3</issue><fpage>S335</fpage><lpage>S344</lpage><history><date date-type="received"><day>08</day><month>12</month><year>2023</year></date><date date-type="accepted"><day>26</day><month>12</month><year>2023</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2024 Indian Journal of Ophthalmology</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncsalicense">https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref><license-p>This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><p>Normal tension glaucoma (NTG) is a complex optic neuropathy characterized by progressive retinal ganglion cell death and glaucomatous visual field loss, despite normal intraocular pressure (IOP). This condition poses a unique clinical challenge due to the absence of elevated IOP, a major risk factor in typical glaucoma. Recent research indicates that up to 21% of NTG patients have a family history of glaucoma, suggesting a genetic predisposition. In this comprehensive review using PubMed studies from January 1990 to December 2023, our focus delves into the genetic basis of autosomal dominant NTG, the only known form of inheritance for glaucoma. Specifically exploring optineurin (<italic toggle="yes">OPTN</italic>), TANK binding kinase 1 (<italic toggle="yes">TBK1</italic>), methyltransferase-like 23 (<italic toggle="yes">METTL23</italic>), and myocilin (<italic toggle="yes">MYOC</italic>) mutations, we summarize their clinical manifestations, mutant protein behaviors, relevant animal models, and potential therapeutic pathways. This exploration aims to illuminate the intricate pathogenesis of NTG, unraveling the contribution of these genetic components to its complex development.</p></abstract><kwd-group><kwd><italic toggle="yes">METTL23</italic></kwd><kwd><italic toggle="yes">MYOC</italic></kwd><kwd>normal tension glaucoma</kwd><kwd><italic toggle="yes">OPTN</italic></kwd><kwd><italic toggle="yes">TBK1</italic></kwd></kwd-group></article-meta></front><body><p>Glaucoma is a major optic neuropathy characterized by optic nerve damage and notable retinal ganglion cell (RGC) loss and is the leading cause of irreversible blindness worldwide.[<xref rid="R1" ref-type="bibr">1</xref>] Primary open-angle glaucoma (POAG) represents the most common type of glaucoma.[<xref rid="R2" ref-type="bibr">2</xref>] The Baltimore Eye Survey reported that more than half of POAG patients do not exhibit elevated intraocular pressure (IOP), defining the case for normal tension glaucoma (NTG).[<xref rid="R3" ref-type="bibr">3</xref>] NTG displays optic nerve head (ONH) damage, progressive retinal nerve fiber layer (RNFL) thinning, distinct visual field defects, open anterior chamber angles upon gonioscopy, and maintains an IOP below 21 mmHg without affecting the rest of the retina.[<xref rid="R4" ref-type="bibr">4</xref>]</p><p>Epidemiologic studies have identified several risk factors associated with NTG, including age, gender, ethnicity, and family history.[<xref rid="R5" ref-type="bibr">5</xref>] First, the average age of NTG patients is in their 60s, generally older than individuals with POAG.[<xref rid="R6" ref-type="bibr">6</xref>] Second, some studies have indicated a higher prevalence of NTG among females than males.[<xref rid="R7" ref-type="bibr">7</xref>] However, this gender difference may be attributed to the longer life expectancy of females. Third, the incidence of NTG varies among different populations. Notably, research has shown a higher NTG prevalence in Asians (52%&#x02013;92%), notably Japanese individuals (92%), compared to those of White ethnicity (30%&#x02013;39%).[<xref rid="R8" ref-type="bibr">8</xref><xref rid="R9" ref-type="bibr">9</xref><xref rid="R10" ref-type="bibr">10</xref><xref rid="R11" ref-type="bibr">11</xref>] In addition, Asian Americans have been found to have a 159% increased risk of NTG compared to non-Hispanic White individuals,[<xref rid="R10" ref-type="bibr">10</xref>] possibly reflecting an increased demographic association and genetic susceptibility. Moreover, approximately 21% of NTG patients have a family history of glaucoma,[<xref rid="R12" ref-type="bibr">12</xref>] further suggesting a genetic predisposition.</p><p>While most forms of glaucoma have a hereditary component, they exhibit different patterns of inheritance. Glaucoma can occur at all ages, with Mendelian inheritance typical for the early-onset familial NTG and juvenile open-angle glaucoma (JOAG) and complex traits evident in adult-onset POAG and primary angle-closure glaucoma.[<xref rid="R11" ref-type="bibr">11</xref>] Notably, gene mutations associated with early-onset glaucoma have significant biological effects, while variants contributing to adult-onset glaucoma typically have more minor effects.[<xref rid="R13" ref-type="bibr">13</xref>]</p><p>To date, genome-wide association studies (GWAS) have successfully identified the genomic loci for POAG.[<xref rid="R11" ref-type="bibr">11</xref>] A recent multiethnic meta-analysis, encompassing 34,179 cases and 349,321 controls (NTG: 3247 cases, 47,997 controls; High-tension glaucoma (HTG): 5144 cases, 47,997 controls), identified 127 loci.[<xref rid="R14" ref-type="bibr">14</xref>] All NTG loci, except rs1812974 near <italic toggle="yes">ARHGEF12</italic>, showed nominal associations with HTG.[<xref rid="R14" ref-type="bibr">14</xref>] In contrast to GWAS, which generally focuses on the common variants with smaller effects (minor allele frequency &#x0003e;1%), NTG pedigree studies have revealed rare mutations in four genes, most of which have been validated through <italic toggle="yes">in vitro</italic> and animal models.[<xref rid="R2" ref-type="bibr">2</xref><xref rid="R15" ref-type="bibr">15</xref>] Numerous large NTG pedigrees have been described, typically demonstrating an autosomal dominant inheritance pattern, suggesting a Mendelian form of glaucoma caused by mutation in a single gene. This review examines the genetic role in NTG, drawing insights from PubMed studies published between January 1990 and December 2023. It delves into rare mutations identified through NTG pedigree studies, exploring pedigree characteristics, clinical features, protein function, mutation effects, and relevant animal models. The insights gained from these discoveries provide new perspectives on the fundamental molecular mechanisms underlying glaucoma, potentially paving the way for novel gene-based therapies and neuroprotection strategies. Furthermore, gene-based diagnostic testing for mutations responsible for NTG promises to detect individuals in the earliest stages of the disease when therapeutic interventions are more effective.</p><sec id="sec1-1"><title>Optineurin (<italic toggle="yes">OPTN</italic>)</title><p>The human optineurin (<italic toggle="yes">OPTN</italic>) gene is located on the short arm of chromosome 10 (10p13) and comprises 15 exons, including two noncoding exons and 13 coding exons [<xref rid="IJO.IJO_3204_23-F1" ref-type="fig">Fig. 1</xref>].[<xref rid="R16" ref-type="bibr">16</xref>] This chromosomal region was previously designated as the <italic toggle="yes">GLC1E</italic> locus for POAG.[<xref rid="R17" ref-type="bibr">17</xref>] Predictions of <italic toggle="yes">OPTN</italic> promoter sequence reveal the presence of multiple nuclear factor kappa B (NF-kB) binding sites within 600 base pairs (bp) of the transcriptional regulatory region.[<xref rid="R16" ref-type="bibr">16</xref>] The <italic toggle="yes">OPTN</italic> gene encodes a 577-amino acid (aa) protein, with two coiled-coil (CC) domains, highly conserved among species.[<xref rid="R18" ref-type="bibr">18</xref>] Furthermore, alternative splicing in the 5&#x02019;-untranslated region produces at least three distinct isoforms, all sharing the same reading frame.[<xref rid="R16" ref-type="bibr">16</xref>]</p><fig position="float" id="IJO.IJO_3204_23-F1"><label>Figure 1</label><caption><p>Disease-associated mutations in <italic toggle="yes">OPTN</italic> gene. (a) <italic toggle="yes">OPTN</italic> gene encodes a 577-amino acid protein with coiled-coil (CC), leucine zipper (LZ), LC3-interacting region (LIR), ubiquitin-binding (UBD), and zinc finger (ZF) domains. (b) Normal tension glaucoma (NTG)-linked mutations (red box: causative; dotted box: risk variants). (c) Amyotrophic lateral sclerosis (ALS)-associated mutations</p></caption><graphic xlink:href="IJO-72-335-g001" position="float"/></fig><sec id="sec2-1"><title><italic toggle="yes">OPTN</italic> mutations in NTG</title><p>In 1998, Sarfarazi <italic toggle="yes">et al</italic>.[<xref rid="R17" ref-type="bibr">17</xref>] reported a four-generation NTG pedigree, comprising 16 affected individuals. Through linkage analysis, a subset of genetic markers within <italic toggle="yes">GLC1E</italic> locus consistently co-segregated with NTG in the pedigree.[<xref rid="R17" ref-type="bibr">17</xref>] Considering the expression in the retina, <italic toggle="yes">OPTN</italic> was identified as the prime candidate gene for further investigation.[<xref rid="R18" ref-type="bibr">18</xref>] Genetic analysis revealed that all family members with NTG carried <italic toggle="yes">OPTN</italic> (c. 458G &#x0003e; A, p.E50K) mutation, conclusively establishing that OPTN<sup>E50K</sup> mutation causes NTG.[<xref rid="R17" ref-type="bibr">17</xref>] <italic toggle="yes">OPTN</italic> was marked as the first gene associated with NTG.[<xref rid="R18" ref-type="bibr">18</xref>] The OPTN<sup>E50K</sup> mutation was detected in approximately 1%&#x02013;2% of NTG patients across various cohorts and was notably absent in matched control populations assembled from clinical settings in the USA, Europe, Japan, and Australia.[<xref rid="R19" ref-type="bibr">19</xref><xref rid="R20" ref-type="bibr">20</xref><xref rid="R21" ref-type="bibr">21</xref>]</p><p>Two additional mutations, <italic toggle="yes">OPTN</italic> c. 691-692insAG (resulting in a premature stop) and OPTN<sup>R545Q</sup> (c. 1634G &#x0003e; A), were initially linked to NTG.[<xref rid="R18" ref-type="bibr">18</xref>] However, regarding the role of OPTN<sup>R545Q</sup> in NTG, subsequent analyses have generated conflicting data, as it was frequently found in both NTG patients and controls.[<xref rid="R16" ref-type="bibr">16</xref><xref rid="R19" ref-type="bibr">19</xref><xref rid="R20" ref-type="bibr">20</xref><xref rid="R21" ref-type="bibr">21</xref><xref rid="R22" ref-type="bibr">22</xref><xref rid="R23" ref-type="bibr">23</xref><xref rid="R24" ref-type="bibr">24</xref>] In addition, a fourth <italic toggle="yes">OPTN</italic> variant, OPTN<sup>M98K</sup> (c.293T&#x0003e;A), was also identified in both NTG-affected cases and controls. Interestingly, the frequency of OPTN<sup>M98K</sup> is statistically higher in NTG patients compared to controls in certain populations,[<xref rid="R21" ref-type="bibr">21</xref><xref rid="R22" ref-type="bibr">22</xref><xref rid="R23" ref-type="bibr">23</xref><xref rid="R24" ref-type="bibr">24</xref><xref rid="R25" ref-type="bibr">25</xref>] and due to its location within the CC domain, it may potentially contribute as a risk for NTG in specific populations.</p><p>Genetic studies have also linked different sets of <italic toggle="yes">OPTN</italic> mutations with amyotrophic lateral sclerosis (ALS), a motor neuron disease.[<xref rid="R26" ref-type="bibr">26</xref>] Several loss-of-function <italic toggle="yes">OPTN</italic> mutations, including R96L, A136V, Q165X, K395R, Q398X, I451T, Q454E, E478G, and E516Q, have been associated with ALS [<xref rid="IJO.IJO_3204_23-F1" ref-type="fig">Fig. 1</xref>].[<xref rid="R26" ref-type="bibr">26</xref>] <italic toggle="yes">OPTN</italic> c.691-692insAG, initially found in an NTG patient, was later identified as a founder mutation in Moroccan and Ashkenazi Jews, significantly increasing the risk of developing ALS in heterozygous carriers.[<xref rid="R27" ref-type="bibr">27</xref>]</p></sec><sec id="sec2-2"><title>Clinical features of <italic toggle="yes">OPTN</italic>-associated NTG</title><p><italic toggle="yes">OPTN</italic>-associated NTG patients typically present with early-onset disease following an autosomal dominant inheritance pattern. Aung <italic toggle="yes">et al</italic>.[<xref rid="R28" ref-type="bibr">28</xref>] conducted a comparative analysis, assessing the clinical features of NTG patients with OPTN<sup>E50K</sup> mutation (<italic toggle="yes">n</italic> = 11) in contrast to NTG patients without glaucoma-causing mutations (<italic toggle="yes">n</italic> = 87). It was observed that patients carrying OPTN<sup>E50K</sup> mutation were diagnosed at a younger age (average of 40.8 &#x000b1; 15) and exhibited larger cup-to-disc (C/D) ratios (mean of 0.86 &#x000b1; 0.1) compared to NTG controls.[<xref rid="R28" ref-type="bibr">28</xref>] Similar clinical findings have been consistently reported in subsequent studies. For instance, Minegishi <italic toggle="yes">et al</italic>.[<xref rid="R16" ref-type="bibr">16</xref>] described a three-generation Japanese pedigree with six family members carrying OPTN<sup>E50K</sup>, diagnosed at an early age (mean of 36.8 years) and displayed low IOP (mean of 13 mmHg). In addition, Hauser <italic toggle="yes">et al</italic>.[<xref rid="R19" ref-type="bibr">19</xref>] reported an OPTN<sup>E50K</sup> NTG patient diagnosed at 38, with normal IOP (15 mmHg in the right eye and 14 mmHg in the left eye) and a C/D ratio of 0.9. Ayala-Lugo <italic toggle="yes">et al</italic>.[<xref rid="R29" ref-type="bibr">29</xref>] also reported an OPTN<sup>E50K</sup> NTG patient diagnosed at 42 years old with a maximum IOP of 18 mmHg and a C/D ratio of 1.0. More recently, Fox and Fingert[<xref rid="R15" ref-type="bibr">15</xref>] documented a four-generation NTG pedigree with six family members carrying OPTN<sup>E50K</sup>, all exhibiting low IOPs (mean of 14.6 &#x000b1; 1.2 mmHg).</p></sec><sec id="sec2-3"><title>OPTN protein function in NTG</title><p>The human OPTN protein is a 64-kDa scaffold protein consisting of 577 aas, while the mouse <italic toggle="yes">Optn</italic> gene encodes a 584-aa protein (67 kDa) that shares a 78% identity with human OPTN.[<xref rid="R30" ref-type="bibr">30</xref>] OPTN is a highly conserved protein expressed ubiquitously in all human organs, including the retina, heart, brain, liver, kidney, placenta, and pancreas.[<xref rid="R18" ref-type="bibr">18</xref>] It exhibits exceptionally high expression in the skeletal muscle.[<xref rid="R18" ref-type="bibr">18</xref>] OPTN encompasses several structural domains, including two CC domains, a leucine zipper (LZ) domain, an LC3-interacting region (LIR), a ubiquitin-binding domain (UBD), and a zinc finger (ZF) domain [<xref rid="IJO.IJO_3204_23-F1" ref-type="fig">Fig. 1</xref>].[<xref rid="R31" ref-type="bibr">31</xref>] Normally, OPTN undergoes posttranslational modifications that significantly affect its function, including phosphorylation and ubiquitination.[<xref rid="R26" ref-type="bibr">26</xref>] One of the major kinases capable of phosphorylating OPTN on at least nine serine and two threonine residues is TANK binding kinase-1 (TBK1).[<xref rid="R32" ref-type="bibr">32</xref>]</p><p>OPTN is a multifunctional protein involved in several cellular processes. First, it acts as an autophagy receptor or adaptor, playing a role in several forms of selective autophagy, including xenophagy,[<xref rid="R33" ref-type="bibr">33</xref>] mitophagy,[<xref rid="R34" ref-type="bibr">34</xref>] and aggrephagy.[<xref rid="R35" ref-type="bibr">35</xref>] Second, it participates in vesicular trafficking,[<xref rid="R36" ref-type="bibr">36</xref>] Golgi maintenance,[<xref rid="R37" ref-type="bibr">37</xref>] secretion,[<xref rid="R38" ref-type="bibr">38</xref>] and receptor recycling.[<xref rid="R39" ref-type="bibr">39</xref><xref rid="R40" ref-type="bibr">40</xref>] Third, OPTN significantly impacts the innate immune response by negatively regulating the NF-kB pathway.[<xref rid="R41" ref-type="bibr">41</xref>] This diversity in the functions of OPTN can be attributed to its ability to interact with numerous potential partners and to be involved with multiple pathways.[<xref rid="R16" ref-type="bibr">16</xref>]</p><p>The effect of OPTN<sup>E50K</sup> on cell survival and other functions in glaucoma has been investigated using cultured cells and transgenic mouse models, as discussed in the following section. Studies utilizing various cell lines have revealed that the OPTN<sup>E50K</sup> mutant induces apoptosis-like cell death in retinal cells, such as RGC-5, 661W, and human primary retinal cells.[<xref rid="R42" ref-type="bibr">42</xref><xref rid="R43" ref-type="bibr">43</xref><xref rid="R44" ref-type="bibr">44</xref>] However, this effect is not observed in several other cell lines tested, including IMR-32, Hela, Cos-1, and NSC34.[<xref rid="R42" ref-type="bibr">42</xref><xref rid="R43" ref-type="bibr">43</xref><xref rid="R44" ref-type="bibr">44</xref>] These findings suggest that the OPTN<sup>E50K</sup> mutant may contribute to glaucoma by directly inducing the death of RGCs. Notably, Minegishi <italic toggle="yes">et al</italic>.[<xref rid="R30" ref-type="bibr">30</xref>] have reported an accumulation of insoluble overexpressed OPTN<sup>E50K</sup> in the endoplasmic reticulum (ER) of HEK293 cells, which aligns with the results obtained from neurons derived from induced pluripotent stem cells from E50K NTG patients (OPTN<sup>E50K</sup> iPSCs). The OPTN<sup>E50K</sup> mutant exhibits a strong interaction with TBK1, hindering the proper oligomerization and solubility of OPTN, both of which are crucial for OPTN&#x02019;s intracellular transition.[<xref rid="R30" ref-type="bibr">30</xref>] Treatment with BX795, a TBK1 inhibitor, effectively reverses the abnormal insolubility of the OPTN<sup>E50K</sup> mutant, which delineates the intracellular dynamics of the endogenous mutant protein, which causes insolubility associated with TBK1, resulting in POAG.[<xref rid="R30" ref-type="bibr">30</xref>]</p><p>In 2020, VanderWall <italic toggle="yes">et al</italic>.[<xref rid="R45" ref-type="bibr">45</xref>] generated OPTN<sup>E50K</sup> iPSCs and observed that RGCs differentiated from OPTN<sup>E50K</sup> iPSCs exhibited numerous neurodegenerative deficits, including neurite retraction, autophagy dysfunction, apoptosis, and increased excitability. Recently, Gomes <italic toggle="yes">et al</italic>.[<xref rid="R46" ref-type="bibr">46</xref>] differentiated RGCs and astrocytes from OPTN<sup>E50K</sup> iPSCs and identified significant changes in OPTN<sup>E50K</sup> astrocytes, including autophagy dysfunction. Co-culture experiments demonstrated that astrocytes induce neurodegenerative properties in otherwise healthy RGCs, while healthy astrocytes alleviate some neurodegenerative features in OPTN (E50K) RGCs.[<xref rid="R46" ref-type="bibr">46</xref>]</p></sec><sec id="sec2-4"><title>OPTN mouse models</title><p>Several mouse models of NTG have been developed to mimic human NTG, primarily caused by the well-characterized OPTN<sup>E50K</sup> mutation [<xref rid="IJO.IJO_3204_23-T1" ref-type="table">Table 1</xref>]. In 2010, Chi <italic toggle="yes">et al</italic>.[<xref rid="R47" ref-type="bibr">47</xref>] generated the first transgenic mouse that highly overexpressed mouse Optn<sup>E50K</sup>, equivalent to human OPTN<sup>E50K</sup>, using the CMV immediate enhancer/&#x003b2;-actin (CAG) promoter. The overexpression of mouse Optn<sup>E50K</sup> led to progressive retinal degeneration, characterized by loss of RGCs and connecting synapses in the peripheral retina. This resulted in a thinning of RNFL at ONH at normal IOP in 16-month-old mice, thus confirming the association between OPTN<sup>E50K</sup> and NTG. Furthermore, Optn<sup>E50K</sup> mice exhibited massive apoptosis and degeneration of the entire retina, leading to approximately 28% reduction in the retina thickness.</p><table-wrap position="float" id="IJO.IJO_3204_23-T1"><label>Table 1</label><caption><p>Overview of OPTN<sup>E50K</sup> mouse models for NTG</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Mouse lines</th><th align="center" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Promotor</th><th align="center" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Main results</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Transgenic mice</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Mouse Optn<sup>E50K</sup></td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CAG (CMV immediate enhancer/&#x003b2;-actin)</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Progressive retinal degeneration is characterized by loss of RGCs and connecting synapses in the peripheral retina, leading to a thinning of the nerve fiber layer at ONH at normal IOP in 16-month-old mice</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">[<xref rid="R47" ref-type="bibr">47</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Human OPTN<sup>E50K</sup></td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">c-kit</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">[<xref rid="R48" ref-type="bibr">48</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">BAC-hOPTN<sup>E50K</sup></td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">BCA with <italic toggle="yes">OPTN</italic> endogenous regulatory sequences</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">More stressed or degenerating optic nerve axons in BAC-hOPTNE50K mice than in 18-month-old control mice at normal IOP</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">[<xref rid="R49" ref-type="bibr">49</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Knock-in mice</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Optn<sup>E50K/E50K</sup></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">The thinning of the RGC fiber layer around ONH from 6 months at normal IOP. At 12 months, the thickness of RGC fiber layer around ONH reduction was 20% compared to WT mice</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">[<xref rid="R16" ref-type="bibr">16</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Optn<sup>E50K/E50K</sup></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Aging-related RGC loss and visual dysfunction without elevated IOP</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">[<xref rid="R50" ref-type="bibr">50</xref>]</td></tr></tbody></table><table-wrap-foot><fn id="TF-F1"><p>BAC=bacterial artificial chromosome, IOP=intraocular pressure, NTG=normal tension glaucoma, ONH=optic nerve head, OPTN=optineurin, RGCs=retinal ganglion cells, WT=wild type</p></fn></table-wrap-foot></table-wrap><p>The following year, Meng <italic toggle="yes">et al</italic>.[<xref rid="R48" ref-type="bibr">48</xref>] generated another transgenic mouse that overexpressed human OPTN<sup>E50K</sup> using the c-kit promoter. However, they only confirmed the expression of human OPTN<sup>E50K</sup> in the retina of this transgenic mouse model and did not measure IOP or histological abnormalities. In 2015, Tseng <italic toggle="yes">et al</italic>.[<xref rid="R49" ref-type="bibr">49</xref>] created the third OPTN transgenic mouse (BAC-hOPTN<sup>E50K</sup>) with low expression of OPTN<sup>E50K</sup> using a bacterial artificial chromosome (BAC) that contained the OPTN promoter region and human <italic toggle="yes">OPTN</italic> gene. Histological analysis revealed a 40% RGC loss with normal IOP. In addition, the study of optic nerve axons revealed stressed and damaged optic nerve axons in BAC-hOPTN<sup>E50K</sup> mice compared to 18-month-old control mice.</p><p>In 2016, Minegishi <italic toggle="yes">et al</italic>.[<xref rid="R16" ref-type="bibr">16</xref>] generated an Optn<sup>E50K</sup> knock-in (KI) mouse model using CRISPR/Cas9 editing. Thinning of the RGC fiber layer around ONH in Optn<sup>E50K</sup> KI homozygous (Optn<sup>E50K/E50K</sup>) mice was observed from 6 months, despite normal IOP. At 12 months, the thickness of the RGC fiber layer around ONH was reduced by 20% compared to wild-type (WT) mice. Furthermore, the optic cup deepened in Optn<sup>E50K/E50K</sup> mice, similar to the changes seen in NTG patients. The administration of TBK1 inhibitor amlexanox proved effective in treating these Optn<sup>E50K</sup> KI mice. Presently, amlexanox holds approvals from both the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) and the US Food and Drug Administration (FDA) for clinical trials. In addition, Hou <italic toggle="yes">et al</italic>.[<xref rid="R50" ref-type="bibr">50</xref>] established another Optn<sup>E50K</sup> KI mouse model and identified aging-related RGCs loss and visual dysfunction in Optn<sup>E50K/E50K</sup> mice without elevated IOP. Electron microscopy results also demonstrated significant morphological anomalies in the mitochondria of RGCs axons in 3-month-old Optn<sup>E50K/E50K</sup> mice, with these changes worsening with age, suggesting that the damaged mitochondria-associated dysfunction of RGCs axon may play an etiological role in NTG.</p></sec></sec><sec id="sec1-2"><title>TANK Binding Kinase-1 (<italic toggle="yes">TBK1</italic>)</title><p><italic toggle="yes">TBK1</italic> is located at 12q14.1 and contains 21 exons, of which exon 1, parts of exon 2, and exon 21 are noncoding [<xref rid="IJO.IJO_3204_23-F2" ref-type="fig">Fig. 2</xref>].[<xref rid="R51" ref-type="bibr">51</xref>] Mutation-associated haploinsufficiency of <italic toggle="yes">TBK1</italic> has been implicated as a causal mutation in several types of neuroinflammatory diseases, including ALS, frontotemporal dementia (FTD), Alzheimer&#x02019;s disease (AD) and related tauopathies, herpes simplex virus-1 (HSV-1) encephalitis (HSE), and atypical parkinsonian syndrome.[<xref rid="R52" ref-type="bibr">52</xref>] Copy number gains of <italic toggle="yes">TBK1</italic> have been associated with NTG, but <italic toggle="yes">TBK1</italic> does not appear to be involved in the pathogenesis of HTG; additional data suggest that <italic toggle="yes">TBK1</italic> is not associated with JOAG, pigmentary glaucoma, or steroid-induced glaucoma.[<xref rid="R15" ref-type="bibr">15</xref>] In this section, we will focus on the role of <italic toggle="yes">TBK1</italic> in NTG.</p><fig position="float" id="IJO.IJO_3204_23-F2"><label>Figure 2</label><caption><p>Disease-associated CNVs spanning <italic toggle="yes">TBK1</italic> gene. (a) <italic toggle="yes">GLC1P</italic> locus includes <italic toggle="yes">TBK1</italic> with flanking <italic toggle="yes">XPOT</italic> and <italic toggle="yes">RASSF3</italic> genes. (b) CNVs duplicating or triplicating <italic toggle="yes">TBK1</italic> in NTG patients (indicated by arrows). (c) <italic toggle="yes">TBK1</italic> gene encodes a 729-amino acid protein with kinase, ubiquitin-like (ULD), coiled-coil (CC), leucine zipper (LZ), and helix&#x02013;loop&#x02013;helix (HLH) domains. CNV = copy number variation, NTG = normal tension glaucoma</p></caption><graphic xlink:href="IJO-72-335-g002" position="float"/></fig><sec id="sec2-5"><title><italic toggle="yes">TBK1</italic> mutations in NTG</title><p>In 2011, linkage analysis of an African-American NTG pedigree mapped a new glaucoma-causing gene to a 780-kbp duplication within the <italic toggle="yes">GLC1P</italic> locus on chromosome 12q14.[<xref rid="R53" ref-type="bibr">53</xref>] Subsequent copy number variation (CNV) analysis and expression analysis of the <italic toggle="yes">GLC1P</italic> locus in retina suggested that <italic toggle="yes">TBK1</italic> duplication is likely responsible for NTG.[<xref rid="R53" ref-type="bibr">53</xref>] Both duplication and triplication of <italic toggle="yes">TBK1</italic> have been detected in NTG pedigrees from Europe, Japan, Australia, and Korea [<xref rid="IJO.IJO_3204_23-T2" ref-type="table">Table 2</xref> and <xref rid="IJO.IJO_3204_23-F2" ref-type="fig">Fig. 2</xref>].[<xref rid="R53" ref-type="bibr">53</xref><xref rid="R54" ref-type="bibr">54</xref><xref rid="R55" ref-type="bibr">55</xref><xref rid="R56" ref-type="bibr">56</xref><xref rid="R57" ref-type="bibr">57</xref>] These <italic toggle="yes">TBK1</italic> CNVs have been detected and confirmed by various molecular genetic techniques, including quantitative polymerase chain reaction (PCR), chromosomal microarray analysis, and genomic sequencing.[<xref rid="R15" ref-type="bibr">15</xref>] The cohort of unrelated NTG patients was also evaluated for <italic toggle="yes">TBK1</italic> mutations. <italic toggle="yes">TBK1</italic> CNV mutations were detected in two (1.3%) of 152 NTG patients from Iowa,[<xref rid="R53" ref-type="bibr">53</xref>] one (0.4%) of 252 Japanese NTG patients,[<xref rid="R54" ref-type="bibr">54</xref>] one (1.0%) of 96 NTG patients from New York,[<xref rid="R58" ref-type="bibr">58</xref>] four (1.2%) of 334 NTG patients from Australia,[<xref rid="R56" ref-type="bibr">56</xref>] two (1.4%) of 143 NTG patients from India,[<xref rid="R59" ref-type="bibr">59</xref>] and one (0.2%) of 143 Korean NTG patients.[<xref rid="R57" ref-type="bibr">57</xref>]</p><table-wrap position="float" id="IJO.IJO_3204_23-T2"><label>Table 2</label><caption><p>Summary of TBK1 CNV detected in NTG pedigrees</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Pedigree (ancestry)</th><th align="center" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">CNV (kb)</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Diagnosed age (years)</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Max IOP (mmHg, OD/OS)/ Cup-to-disc ratio (first examination, OD/OS)</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">GGO-441 (African-American)</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Duplication (690&#x02013;780)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">36&#x000b1;8.2</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">18.2&#x000b1;4.1/16.7&#x000b1;3.6/ 0.95&#x000b1;0.083/0.93&#x000b1;0.10</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">[<xref rid="R53" ref-type="bibr">53</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">GGA-458 (German)</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Triplication (646)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">29&#x000b1;6.7</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">19.0&#x000b1;4.3/18.8&#x000b1;3.8/ 0.85&#x000b1;0.071/0.85&#x000b1;0.071</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">[<xref rid="R55" ref-type="bibr">55</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">GGJ-414 (Japanese)</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Duplication (296)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">42 (II-4)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">18/17 (II-4)/ 0.75/0.7 (II-4)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">[<xref rid="R54" ref-type="bibr">54</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">AG604 (Australian)</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Triplication (347)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">60 (AG604)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">12/12 (AG604)/ 0.95/0.95 (AG604)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">[<xref rid="R56" ref-type="bibr">56</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">AG624 (Australian)</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Duplication (406)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">44 (AG624)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">17/17 (AG624)/ 0.95/0.90 (AG624)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">[<xref rid="R56" ref-type="bibr">56</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">AG724 (Australian)</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Duplication (406)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">43 (AG724)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">14/14 (AG724)/ 0.80/0.90 (AG724)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">[<xref rid="R56" ref-type="bibr">56</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">GFMC524 (Australian)</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Duplication (442)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">32 (GFMC524)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">13/13 (GFMC524)/ 0.85/0.85 (GFMC524)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">[<xref rid="R56" ref-type="bibr">56</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">S227 (Korean)</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Duplication (124)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">48&#x000b1;16 (39&#x02013;68)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">15.0&#x000b1;1.7/15.0&#x000b1;2/ -</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">[<xref rid="R57" ref-type="bibr">57</xref>]</td></tr></tbody></table><table-wrap-foot><fn id="TF-F2"><p>CNV=copy number variation, IOP=intraocular pressure, NTG=normal tension glaucoma, OD/OS=oculus dexter/oculus sinister, TBK1=TANK binding kinase 1</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec2-6"><title>Clinical features of <italic toggle="yes">TBK1</italic>-associated NTG</title><p>Patients with NTG associated with <italic toggle="yes">TBK1</italic> duplication or triplication have typical clinical findings of glaucoma. The presenting features of NTG in seven members of the first <italic toggle="yes">TBK1</italic> pedigree from African-Americans (GGO-441) include: 1) an early age at diagnosis with a mean of 36 &#x000b1; 8.2 years; 2) low IOP with a mean of 18.2 &#x000b1; 4.1/16.7 &#x000b1; 3.6 mmHg (oculus dexter/oculus sinister [OD/OS]); and 3) large C/D ratios with a mean of 0.95 &#x000b1; 0.083/0.93 &#x000b1; 0.10 (OD/OS).[<xref rid="R53" ref-type="bibr">53</xref>] Similar clinical findings were observed in other reported <italic toggle="yes">TBK1</italic>-associated NTG pedigrees, including GGA-458, GGJ-414, AG624, AG724, and GFMC524.[<xref rid="R53" ref-type="bibr">53</xref><xref rid="R54" ref-type="bibr">54</xref><xref rid="R55" ref-type="bibr">55</xref><xref rid="R56" ref-type="bibr">56</xref><xref rid="R57" ref-type="bibr">57</xref>] These family members also had an early onset of NTG (diagnosed before age 45) and a large C/D ratio, as summarized in <xref rid="IJO.IJO_3204_23-T2" ref-type="table">Table 2</xref>.</p></sec><sec id="sec2-7"><title>TBK1 function in NTG</title><p>TBK1 is an 82-kDa protein consisting of 729 aa and comprises a kinase domain, a ubiquitin-like domain, and CC domains 1 and 2.[<xref rid="R16" ref-type="bibr">16</xref>] It is conserved across eukaryotes, with human paralogs identified in zebrafish, mice, primates, and amphibians. Mouse and human TBK1 exhibit a significant level of sequence similarity, sharing at least 94% homology.[<xref rid="R52" ref-type="bibr">52</xref>] TBK1 belongs to the non-canonical I&#x003ba;B kinase (IKK) family and displays 64% homology to IKK&#x003b5; (also known as IKKi), which plays a critical role in regulating the balance between interferon-1 (IFN-1) and IFN-II signaling pathways.[<xref rid="R60" ref-type="bibr">60</xref>]</p><p>TBK1, also known as NF-kB activating kinase (NAK) and T2K, is a serine/threonine protein kinase that plays a key role in the regulation of various cellular processes, including innate immunity, inflammatory cytokine production, autophagy, mitochondrial metabolism, and cell survival/proliferation.[<xref rid="R52" ref-type="bibr">52</xref>] TBK1 can be activated by pathogen-associated molecular patterns, damage-associated molecular patterns, inflammatory cytokines, and oncogenic kinases.[<xref rid="R60" ref-type="bibr">60</xref>] Its biological activity was initially recognized in innate defenses against pathogens, where it plays a crucial role in regulating the production of type I IFN, including IFN-&#x003b1; and IFN-&#x003b2;.[<xref rid="R52" ref-type="bibr">52</xref>] Recent studies have shown that TBK1 connects the pathogen-stimulated processes of inflammation/immunity, metabolism, and proliferation in diseases, including inflammatory diseases, type II diabetes, obesity, neurovegetative diseases, and some cancers.[<xref rid="R60" ref-type="bibr">60</xref>]</p><p><italic toggle="yes">TBK1</italic> gene duplications lead to increased <italic toggle="yes">TBK1</italic> mRNA transcription in human fibroblast cells.[<xref rid="R60" ref-type="bibr">60</xref>] However, the details of how the excess <italic toggle="yes">TBK1</italic> can cause RGC death and NTG remain unknown. There are three hypotheses that warrant further investigation: 1) studies of RGCs with a <italic toggle="yes">TBK1</italic> duplication derived from induced pluripotent stem cells (iPSCs) have suggested that this mutation is associated with changes in autophagy;[<xref rid="R61" ref-type="bibr">61</xref>] 2) stimulation of inflammation and the innate immune system by TBK1 might contribute to RGC death and NTG by production of proinflammatory cytokines and glial cell activation, which have been observed in studies of other neurogenerative diseases;[<xref rid="R15" ref-type="bibr">15</xref>] and 3) TBK1 may influence NF-kB signaling upstream of IKK complex.[<xref rid="R52" ref-type="bibr">52</xref>] Further research is needed to clarify these potential mechanisms related to excess <italic toggle="yes">TBK1</italic> expression in NTG.</p></sec><sec id="sec2-8"><title><italic toggle="yes">TBK1</italic> mouse model</title><p>The <italic toggle="yes">TBK1</italic> mouse model (Tg-TBK1) was generated using a BAC vector to integrate the natural human <italic toggle="yes">TBK1</italic> gene into the mouse genome.[<xref rid="R62" ref-type="bibr">62</xref>] This transgene provides the mouse line with an additional copy of <italic toggle="yes">TBK1</italic> gene to mimic the <italic toggle="yes">TBK1</italic> duplications that cause NTG in humans. Increased <italic toggle="yes">TBK1</italic> expression was detected in RGCs of Tg-TBK1 mice. Furthermore, Tg-TBK1 mice developed RGC loss that increased with age at normal IOP.[<xref rid="R62" ref-type="bibr">62</xref>] Heterozygous Tg-TBK1 mice exhibited a 13% RGC loss at 18 months of age compared to controls, while homozygous Tg-TBK1 mice had a 20% loss at 6 months.</p></sec></sec><sec id="sec1-3"><title>Methyltransferase-like 23 (<italic toggle="yes">METTL23</italic>)</title><p>Human methyltransferase-like 23 <italic toggle="yes">(METTL23)</italic> is located at 17q25.1 and comprises five exons, with exon 1 and a part of exon 2 being noncoding [<xref rid="IJO.IJO_3204_23-F3" ref-type="fig">Fig. 3</xref>]. METTL23 functions as a histone arginine methyltransferase. Several pathogenic variants of <italic toggle="yes">METTL23</italic> are associated with familial NTG and familial intellectual disability [<xref rid="IJO.IJO_3204_23-F3" ref-type="fig">Fig. 3</xref>],[<xref rid="R2" ref-type="bibr">2</xref><xref rid="R63" ref-type="bibr">63</xref>] suggesting potential etiologic links among arginine methylation, nervous system disorders, and glaucoma.[<xref rid="R1" ref-type="bibr">1</xref>]</p><fig position="float" id="IJO.IJO_3204_23-F3"><label>Figure 3</label><caption><p>Disease-associated variants in <italic toggle="yes">METTL23</italic> gene<italic toggle="yes">.</italic> (a) <italic toggle="yes">METTL23</italic> consists of five exons; exon 1 and part 2 are noncoding. Several pathogenic variants in <italic toggle="yes">METTL23</italic> have been reported to be associated with normal tension glaucoma (NTG) (b) and familial intellectual disability (c). Red box: causal mutation; dotted box: risk variant</p></caption><graphic xlink:href="IJO-72-335-g003" position="float"/></fig><sec id="sec2-9"><title><italic toggle="yes">METTL23</italic> mutations</title><p>Recently, in a whole exon data analysis involving 11 samples from three-generation Japanese NTG pedigree (comprising six affected and five unaffected), <italic toggle="yes">METTL23</italic> and <italic toggle="yes">CEP290</italic> were identified as the putative NTG-causing genes.[<xref rid="R2" ref-type="bibr">2</xref>] The <italic toggle="yes">in silico</italic> predictive tool (Human splicing Finder) indicated that <italic toggle="yes">METTL23</italic> c.A83G causes abnormal splicing, resulting in functionally null proteins, whereas the <italic toggle="yes">CEP290</italic> variant was excluded due to its low pathogenicity score. The <italic toggle="yes">METTL23</italic> c.A83G mutation was heterozygous in all NTG patients. This allele was transmitted vertically from the affected parents to the affected children, indicating an autosomal dominant inheritance pattern.[<xref rid="R2" ref-type="bibr">2</xref>] No additional exon-spanning duplications or deletions were detected in any of the patients, and no <italic toggle="yes">TBK1</italic> CNVs were detected.[<xref rid="R2" ref-type="bibr">2</xref>] In addition, the <italic toggle="yes">METTL23</italic> c.A83G mutation is not found in any other glaucoma patients enrolled in the Japan Whole Exome Project.[<xref rid="R2" ref-type="bibr">2</xref>]</p><p>A second <italic toggle="yes">METTL23</italic> variant<italic toggle="yes">,</italic> specifically <italic toggle="yes">METTL23</italic> c.84+60delAT, was identified in 14 individuals from 1029 unrelated Japanese NTG cases and found in eight of 1402 age-matched Japanese controls.[<xref rid="R2" ref-type="bibr">2</xref>] No <italic toggle="yes">TBK1</italic> CNVs or OPTN<sup>E50K</sup> mutations were detected in any NTG patient with the <italic toggle="yes">METTL23</italic> c.84+60delAT variant. The distribution of this allele between the patients and controls suggests a potential contribution to NTG, as indicated by statistical tests (<italic toggle="yes">P</italic> = 0.03, Fisher&#x02019;s exact test or c<sup>2</sup> with Yates&#x02019; correction; <italic toggle="yes">P</italic> = 0.038, logistic regression adjusting for age and sex).[<xref rid="R2" ref-type="bibr">2</xref>] However, further work, including analyses of additional data sets, will be necessary to confirm and further explore this finding.</p></sec><sec id="sec2-10"><title>Clinical features of <italic toggle="yes">METTL23</italic>-associated NTG</title><p>Patients carrying <italic toggle="yes">METT23</italic> c.A83G have typical clinical characteristics of NTG, including 1) early age at diagnosis, with a mean age of 47 &#x000b1; 9.6 years; 2) low IOP with a mean of 15.4 &#x000b1; 3.5 in the right eye and 14.6 &#x000b1; 2.9 mmHg in the left eye; and 3) large C/D ratios with a mean of 0.88 &#x000b1; 0.05 in the right eye and 0.88 &#x000b1; 0.04 in the left eye at the first examination.[<xref rid="R2" ref-type="bibr">2</xref>] None of the affected individuals with <italic toggle="yes">METT23</italic> c.A83G had a history of developmental delay or retinal disease.</p><p>NTG patients carrying <italic toggle="yes">METTL23</italic> c.84+60delAT had distinct clinical characteristics, including 1) a mean age at diagnosis of 62.3 &#x000b1; 12.0 years, 2) maximum IOP with a mean of 15.0 &#x000b1; 2.8/15.0 &#x000b1; 2.6 (OD/OS), and 3) C/D ratio of 0.76 &#x000b1; 0.07/0.82 &#x000b1; 0.11 (OD/OS).[<xref rid="R2" ref-type="bibr">2</xref>] Interestingly, NTG patients with <italic toggle="yes">METT23</italic> c.A83G had an earlier onset of disease and a larger C/D ratio at the initial examination than those with <italic toggle="yes">METTL23</italic> c.84+60delAT. Though the sample size is limited, these data suggest that <italic toggle="yes">METT23</italic> c.A83G mutation may lead to more severe NTG than <italic toggle="yes">METTL23</italic> c.84+60delAT.</p></sec><sec id="sec2-11"><title>METTL23 function in NTG</title><p>METTL23 is expressed at low levels, but is found ubiquitously in human tissues.[<xref rid="R2" ref-type="bibr">2</xref>] It belongs to a methyltransferase-like (METTL) family and shares homology with the conserved domains related to protein arginine methyltransferases (PRMT) activity, particularly PRMT1&#x02013;8.[<xref rid="R64" ref-type="bibr">64</xref><xref rid="R65" ref-type="bibr">65</xref>] In 2017, Hatanaka <italic toggle="yes">et al</italic>.[<xref rid="R64" ref-type="bibr">64</xref>] demonstrated that METTL23 possesses PRMT activity. It catalyzes the dimethylation of histone H3 at arginine 17 (H3R17). This enzymatic activity suggests that METTL23 plays a role in histone arginine methylation, which may affect gene expression regulation and cellular processes.</p><p>The aberrant splicing by <italic toggle="yes">METT23</italic> c.A83G mutation at the end of <italic toggle="yes">METTL23</italic> exon 2 was confirmed in various experimental models, including exon-trapping vector transfected HEK293T cells, iPSCs derived from NTG patients, and the retinas of <italic toggle="yes">Mettl23</italic> KI mice. NF-&#x003ba;B transcription factors play an important role in regulating the immune response, while PS2 (small secreted protein that belongs to the trefoil factor family) has been shown to suppress the NF-&#x003ba;B&#x02013;activated expression of proinflammatory cytokines like tumor necrosis factor-alpha (TNF-&#x003b1;) and interleukin (IL)-1&#x003b2;.[<xref rid="R66" ref-type="bibr">66</xref><xref rid="R67" ref-type="bibr">67</xref>] Elevated expression of TNF-&#x003b1; and IL-1&#x003b2; by activated microglial cells in hypoxic neonatal retina has been linked to RGC apoptosis.[<xref rid="R68" ref-type="bibr">68</xref><xref rid="R69" ref-type="bibr">69</xref>] METTL23 was expressed in RGCs and was found to be associated with NF-&#x003ba;B&#x02013;mediated transcription of TNF-&#x003b1; and IL-1&#x003b2; through dimethylation of histone 3 arginine 17 (H3R17).[<xref rid="R2" ref-type="bibr">2</xref>]</p><p>Both <italic toggle="yes">METTL23</italic> c.A83G mutation and METTL23 deficiency were associated with RGC loss and axonal degeneration at ONH in <italic toggle="yes">Mettl23</italic>-KI and -KO mice, similar to the findings in NTG patients. Similarly, <italic toggle="yes">METTL23</italic> c.84+60delAT mutation led to partially aberrant splicing in exon-trapping vector-transfected HEK293T cells, consistent with the milder clinical features observed in NTG patients with this mutation. These findings suggest a direct link among METTL23, histone methylation, immune response regulation, and RGC degeneration in NTG.</p></sec><sec id="sec2-12"><title><italic toggle="yes">METTL23</italic> mouse model</title><p>The mouse models of <italic toggle="yes">METTL23</italic> c.A83G-KI and <italic toggle="yes">METTL23</italic>-knockout (KO) generated by CRISPR/Cas9 demonstrated key pathological features relevant to glaucoma: 1) Ganglion cell complex (GCC) thickness reduction. In B-circular scans focused on ONH, both homozygous <italic toggle="yes">Mettl2</italic>3-KI and -KO mice exhibited a reduction in GCC thickness starting at 2 months of age with normal IOP. This reduction was observed to progress in all <italic toggle="yes">Mettl23</italic>-KI and -KO mice by 6 months of age. 2) Optic nerve injury. Optic nerve fiber injury was evident in optic nerve cross sections, with statistically significant differences observed in both <italic toggle="yes">Mettl23</italic>-KI and -KO mice compared to control mice at 2 and 6 months. 3) RGC deficiency. Slight reductions in photopic negative scotopic threshold response (pSTR) amplitudes were noted in <italic toggle="yes">Mettl23</italic>-KI and -KO mice at 2 months of age. These reductions became more significant at 6 months of age, indicating a substantial loss of RGCs. 4) RGC loss. Examination of retinal whole mounts revealed a slight, though insignificant, decrease in RGCs in both <italic toggle="yes">Mettl23</italic>-KI and -KO mice compared to controls at 2 months, which developed significant RGC loss at 6 months. These findings support the conclusion that RGC degeneration in the <italic toggle="yes">Mettl23</italic>-KI and -KO mouse models is a progressive process, beginning with the axonal injury that precedes the loss of RGCs. This pattern of disease progression in the mouse models resembles the pathophysiological changes observed in NTG patients. Therefore, the <italic toggle="yes">Mettl23</italic>-KI and -KO mouse models provide valuable insights for studying specific aspects of glaucoma, particularly in cases with normal IOP.</p></sec></sec><sec id="sec1-4"><title>Myocilin (<italic toggle="yes">MYOC</italic>)</title><p>The human myocilin (<italic toggle="yes">MYOC</italic>) gene is located on chromosome 1q24 and spans approximately 17 kb. It comprises three exons and two intros.[<xref rid="R70" ref-type="bibr">70</xref>] Initially, <italic toggle="yes">MYOC</italic> was referred to as &#x0201c;the trabecular meshwork inducible glucocorticoid response&#x0201d; (<italic toggle="yes">TIGR</italic>) gene, but it was later renamed <italic toggle="yes">MYOC.</italic>[<xref rid="R71" ref-type="bibr">71</xref>] This gene was the first to be associated with POAG.[<xref rid="R72" ref-type="bibr">72</xref>]</p><sec id="sec2-13"><title><italic toggle="yes">MYOC</italic> mutations in POAG</title><p>More than 100 POAG-associated mutations have been identified in <italic toggle="yes">MYOC</italic> gene, accounting for 3%&#x02013;5% of POAG cases.[<xref rid="R73" ref-type="bibr">73</xref>] Specific mutations in <italic toggle="yes">MYOC</italic> gene can cause POAG with varying ages of onset and degrees of severity. One of the significant associations is with JOAG, characterized by autosomal dominant inheritance and highly penetrant severe phenotype with markedly elevated IOP (greater than 50 mmHg).[<xref rid="R15" ref-type="bibr">15</xref>] Another notable variant is the <italic toggle="yes">MYOC</italic> p.Q368T (rs74315329) variant, which is linked to a less-severe form (IOP &#x0003c;30 mmHg). This variant is more commonly observed in adult-onset POAG, the most prevalent form (approximately 1.6% of POAG patients).[<xref rid="R15" ref-type="bibr">15</xref>]</p></sec><sec id="sec2-14"><title><italic toggle="yes">MYOC</italic> mutations in NTG</title><p>Mutations in <italic toggle="yes">MYOC</italic>, including p.W286R and p.Q368T, have also been detected in NTG patients.[<xref rid="R74" ref-type="bibr">74</xref><xref rid="R75" ref-type="bibr">75</xref><xref rid="R76" ref-type="bibr">76</xref>] However, the presence of these mutations in NTG patients has been subjected to some controversy and variability in different studies. In 2019, a case&#x02013;control study identified the p.Q368T mutation in 11 (0.8%) of 1333 NTG patients and 17 (0.4%) of 4758 controls. This finding suggested a potential association, with <italic toggle="yes">P</italic> = 0.04 and an odds ratio of 2.3.[<xref rid="R77" ref-type="bibr">77</xref>] However, this association was not replicated in a more extensive study of 218,792 Finnish citizens.[<xref rid="R78" ref-type="bibr">78</xref>] In addition, the prevalence of the <italic toggle="yes">MTOC</italic> p.Q368T mutation is higher in POAG patients (1.6%), who typically have elevated IOP, compared to NTG patients (0.8%), indicating that this mutation is more strongly associated with POAG with elevated IOP.[<xref rid="R77" ref-type="bibr">77</xref><xref rid="R79" ref-type="bibr">79</xref>]</p></sec><sec id="sec2-15"><title><italic toggle="yes">MYOC</italic> function</title><p>In humans and mice, <italic toggle="yes">MYOC</italic> is expressed in numerous ocular tissues, with its most prominent presence being in trabecular meshwork (TM).[<xref rid="R80" ref-type="bibr">80</xref>] This expression is known to be induced in cultured human TM cells by various factors, including glucocorticoids, oxidative stress, cell stress signaling pathways, and potentially unidentified factors in the aqueous humor.[<xref rid="R81" ref-type="bibr">81</xref><xref rid="R82" ref-type="bibr">82</xref>] Normally, TM cells secrete MYOC; however, mutations in <italic toggle="yes">MYOC</italic> can disrupt the secretion of both mutant and WT <italic toggle="yes">MYOC</italic>.[<xref rid="R83" ref-type="bibr">83</xref>] Notably, TM plays an important role in regulating IOP, with elevated IOP being the primary risk factor associated with glaucoma, but not for NTG. Despite extensive research, the precise function of MYOC in the retina remains unknown, but it appears to affect TM and the outflow of aqueous humor.[<xref rid="R70" ref-type="bibr">70</xref>] The genetic association and functional relevance to NTG are still under investigation.</p></sec><sec id="sec2-16"><title><italic toggle="yes">MYOC</italic> animal models</title><p>Several groups have used mouse genetics to gain insights into the normal and pathological functions of MYOC in retina. In 2001, Kim <italic toggle="yes">et al</italic>.[<xref rid="R84" ref-type="bibr">84</xref>] generated null mutations in mice, not resulting in a glaucoma phenotype. These findings helped elucidate genetic studies of glaucoma in human patients; a likely null mutation was identified as unrelated to glaucoma in humans.[<xref rid="R85" ref-type="bibr">85</xref>] Furthermore, in 2004, Gould <italic toggle="yes">et al</italic>.[<xref rid="R86" ref-type="bibr">86</xref>] observed that mice overexpressing mouse Myoc also did not develop elevated IOP or glaucoma. Conversely, more than 90% of glaucoma-related mutations affect the highly conserved functional domain of MYOC, known as the olfactomedin domain, likely affecting the structure.[<xref rid="R87" ref-type="bibr">87</xref>] The results from genetic models suggested that MYOC does not have a significant role in regulating IOP, and mutated MYOC with abnormal function (gain of function) was likely responsible for ocular hypertension.</p><p>Subsequently, several groups began testing disease-specific MYOC<sup>Y437H</sup> mutation in mice, a mutation responsible for a severe form of JOAG. Expression of human MYOC<sup>Y437H</sup> and mouse Myoc with a mutation orthologous to Y437H did not lead to RGC loss.[<xref rid="R80" ref-type="bibr">80</xref>] An important discovery was made when Shepard <italic toggle="yes">et al</italic>.[<xref rid="R88" ref-type="bibr">88</xref>] used the adenovirus to express human MYOC<sup>Y437H</sup> in the iridocorneal angle and observed elevated IOP. It is worth noting that human MYOC contains a targeting signal for peroxisomes that does not exist in mouse Myoc, which appears to be critical for the toxicity induced by mutant MYOC in TM cells.[<xref rid="R88" ref-type="bibr">88</xref>] Subsequently, three other groups have reported IOP elevation using different strategies to express human MYOC<sup>Y437H</sup> in mouse eyes.[<xref rid="R80" ref-type="bibr">80</xref>] Other <italic toggle="yes">MYOC</italic> mutations are also believed to involve alternative pathogenic mechanisms.[<xref rid="R80" ref-type="bibr">80</xref>] However, to date, there are still no animal models specifically linked between the <italic toggle="yes">MYOC</italic> gene and NTG.</p></sec></sec><sec sec-type="conclusion" id="sec1-5"><title>Conclusion</title><p>To date, only three genes (<italic toggle="yes">OPTN</italic>, <italic toggle="yes">TBK1,</italic> and <italic toggle="yes">METTL23</italic>) have been linked to familial NTG. Both OPTN and TBK1 proteins play essential roles in NF-&#x003ba;B signaling and autophagy. Furthermore, they share common upstream signals and regulators and can mutually influence each other through positive or negative feedback loops.[<xref rid="R11" ref-type="bibr">11</xref><xref rid="R31" ref-type="bibr">31</xref><xref rid="R32" ref-type="bibr">32</xref><xref rid="R60" ref-type="bibr">60</xref><xref rid="R67" ref-type="bibr">67</xref>] Recently, METTL23 has been shown to catalyze the dimethylation of H3R17 and upregulate SP2 transcription both <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic>, along with TNF-&#x003b1; and IL-1&#x003b2; <italic toggle="yes">in vivo</italic>.[<xref rid="R2" ref-type="bibr">2</xref>] TNF-&#x003b1; and IL-1&#x003b2; are particularly significant for RGCs and optic nerve fibers. The loss of SP2 is associated with NF-&#x003ba;B&#x02013;mediated activation of TNF-&#x003b1; and IL-1&#x003b2; <italic toggle="yes">in vivo</italic>.[<xref rid="R66" ref-type="bibr">66</xref>] Consequently, similar to OPTN and TBK1, METTL23 may also negatively regulate NF-&#x003ba;B&#x02013;mediated TNF-&#x003b1; and IL-1&#x003b2; expression. These findings suggest that the other proteins involved in NF-&#x003ba;B signaling may also contribute to the development of NTG, and the modulation of NF-&#x003ba;B signaling could be a potential direction for the development of therapeutics.</p><p>Research into the role of histone arginine methylation in the development of neuronal diseases is rapidly advancing. The <italic toggle="yes">METTL23</italic> gene has recently been linked to histone arginine methylation in NTG.[<xref rid="R2" ref-type="bibr">2</xref>] In addition to NTG, mutations in <italic toggle="yes">OPTN</italic> and <italic toggle="yes">TBK1</italic> genes have been identified in patients with ALS.[<xref rid="R15" ref-type="bibr">15</xref>] Another gene associated with ALS, ataxin 2 (<italic toggle="yes">ATXN2</italic>), has also been linked to POAG.[<xref rid="R89" ref-type="bibr">89</xref><xref rid="R90" ref-type="bibr">90</xref>] Furthermore, ALS-linked mutations in the RNA-binding protein fused in sarcoma (FUS) result in the formation of insoluble intracytoplasmic protein aggregates.[<xref rid="R91" ref-type="bibr">91</xref>] This process was found to be alleviated by the depletion of PRMT1, which serves as a transcriptional coactivator by depositing dimethylarginines on histone H4R3.[<xref rid="R92" ref-type="bibr">92</xref>] Specifically, <italic toggle="yes">METTL23</italic> c.A83G mutation was shown to hinder the dimethylation of histone H3R17, leading to the onset of NTG.[<xref rid="R2" ref-type="bibr">2</xref>] Notably, several pathogenic variants of <italic toggle="yes">METTL23</italic> are also associated with familial intellectual disability,[<xref rid="R2" ref-type="bibr">2</xref><xref rid="R63" ref-type="bibr">63</xref>] indicating a possible connection among arginine methylation, nervous system disorders, and glaucoma.</p><p>NTG is an irreversible blinding disease, and its diagnosis is more complex compared to high-pressure forms of glaucoma. Understanding the role of NF-&#x003ba;B&#x02013;mediated inflammation in NTG could serve as a catalyst for the development of novel diagnostic and therapeutic approaches. Considering that the optic nerve is part of the central nervous system, these findings may also have broader implications for understanding the pathogenesis of other neurodegenerative diseases.</p><sec sec-type="funding-statement" id="sec2-17"><title>Financial support and sponsorship</title><p>This work has been supported by a research grant to TI by the Japan Agency for Medical Research and Development (AMED, 15ek0109072h0003, 16ek0109072h0003, 17ek0109282s0001, 18ek0109282h0002, 19ek0109282h0003); the Japanese Ministry of Health, Labor, and Welfare (H22-Kankaku-Ippan-002); and the National Hospital Organization (R2-NHO (Kankaku)-02). This work was also supported by grants to YP by the Japan Society for the Promotion of Science (JSPS KAKENHI Grant Numbers 20K18366 and 23K15923).</p></sec><sec sec-type="COI-statement" id="sec2-18"><title>Conflicts of interest</title><p>There are no conflicts of interest.</p></sec></sec></body><back><ref-list><title>References</title><ref id="R1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>WW</given-names></name>
<name><surname>Sun</surname><given-names>Y</given-names></name></person-group><article-title>Epigenetics in glaucoma: A link between histone methylation and neurodegeneration</article-title><source>J Clin Invest</source><year>2022</year><volume>132</volume><fpage>e163670</fpage><pub-id pub-id-type="pmid">36317630</pub-id>
</element-citation></ref><ref id="R2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pan</surname><given-names>Y</given-names></name>
<name><surname>Suga</surname><given-names>A</given-names></name>
<name><surname>Kimura</surname><given-names>I</given-names></name>
<name><surname>Kimura</surname><given-names>C</given-names></name>
<name><surname>Minegishi</surname><given-names>Y</given-names></name>
<name><surname>Nakayama</surname><given-names>M</given-names></name>
<etal/></person-group><article-title>METTL23 mutation alters histone H3R17 methylation in normal-tension glaucoma</article-title><source>J Clin Invest</source><year>2022</year><volume>132</volume><fpage>e153589</fpage><pub-id pub-id-type="pmid">36099048</pub-id>
</element-citation></ref><ref id="R3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sommer</surname><given-names>A</given-names></name>
<name><surname>Tielsch</surname><given-names>JM</given-names></name>
<name><surname>Katz</surname><given-names>J</given-names></name>
<name><surname>Quigley</surname><given-names>HA</given-names></name>
<name><surname>Gottsch</surname><given-names>JD</given-names></name>
<name><surname>Javitt</surname><given-names>J</given-names></name>
<etal/></person-group><article-title>Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey</article-title><source>Arch Ophthalmol</source><year>1991</year><volume>109</volume><fpage>1090</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">1867550</pub-id>
</element-citation></ref><ref id="R4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>MJ</given-names></name></person-group><article-title>Normal tension glaucoma in Asia: Epidemiology, pathogenesis, diagnosis, and management</article-title><source>Taiwan J Ophthalmol</source><year>2020</year><volume>10</volume><fpage>250</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">33437596</pub-id>
</element-citation></ref><ref id="R5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ahrlich</surname><given-names>KG</given-names></name>
<name><surname>De Moraes CG</surname><given-names>V</given-names></name>
<name><surname>Teng</surname><given-names>CC</given-names></name>
<name><surname>Prata</surname><given-names>TS</given-names></name>
<name><surname>Tello</surname><given-names>C</given-names></name>
<name><surname>Ritch</surname><given-names>R</given-names></name>
<etal/></person-group><article-title>Visual field progression differences between normal-tension and exfoliative high-tension glaucoma</article-title><source>Invest Ophthalmol Vis Sci</source><year>2010</year><volume>51</volume><fpage>1458</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">20042657</pub-id>
</element-citation></ref><ref id="R6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bonomi</surname><given-names>L</given-names></name>
<name><surname>Marchini</surname><given-names>G</given-names></name>
<name><surname>Marraffa</surname><given-names>M</given-names></name>
<name><surname>Bernardi</surname><given-names>P</given-names></name>
<name><surname>De Franco</surname><given-names>I</given-names></name>
<name><surname>Perfetti</surname><given-names>S</given-names></name>
<etal/></person-group><article-title>Prevalence of glaucoma and intraocular pressure distribution in a defined population. The Egna-Neumarkt Study</article-title><source>Ophthalmology</source><year>1998</year><volume>105</volume><fpage>209</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">9479277</pub-id>
</element-citation></ref><ref id="R7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dielemans</surname><given-names>I</given-names></name>
<name><surname>Vingerling</surname><given-names>JR</given-names></name>
<name><surname>Wolfs</surname><given-names>RC</given-names></name>
<name><surname>Hofman</surname><given-names>A</given-names></name>
<name><surname>Grobbee</surname><given-names>DE</given-names></name>
<name><surname>de Jong</surname><given-names>PT</given-names></name></person-group><article-title>The prevalence of primary open-angle glaucoma in a population-based study in The Netherlands. The Rotterdam study</article-title><source>Ophthalmology</source><year>1994</year><volume>101</volume><fpage>1851</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">7800368</pub-id>
</element-citation></ref><ref id="R8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Klein</surname><given-names>BE</given-names></name>
<name><surname>Klein</surname><given-names>R</given-names></name>
<name><surname>Sponsel</surname><given-names>WE</given-names></name>
<name><surname>Franke</surname><given-names>T</given-names></name>
<name><surname>Cantor</surname><given-names>LB</given-names></name>
<name><surname>Martone</surname><given-names>J</given-names></name>
<etal/></person-group><article-title>Prevalence of glaucoma. The Beaver Dam eye study</article-title><source>Ophthalmology</source><year>1992</year><volume>99</volume><fpage>1499</fpage><lpage>504</lpage><pub-id pub-id-type="pmid">1454314</pub-id>
</element-citation></ref><ref id="R9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cho</surname><given-names>HK</given-names></name>
<name><surname>Kee</surname><given-names>C</given-names></name></person-group><article-title>Population-based glaucoma prevalence studies in Asians</article-title><source>Surv Ophthalmol</source><year>2014</year><volume>59</volume><fpage>434</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">24837853</pub-id>
</element-citation></ref><ref id="R10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stein</surname><given-names>JD</given-names></name>
<name><surname>Kim</surname><given-names>DS</given-names></name>
<name><surname>Niziol</surname><given-names>LM</given-names></name>
<name><surname>Talwar</surname><given-names>N</given-names></name>
<name><surname>Nan</surname><given-names>B</given-names></name>
<name><surname>Musch</surname><given-names>DC</given-names></name>
<etal/></person-group><article-title>Differences in rates of glaucoma among Asian Americans and other racial groups, and among various Asian ethnic groups</article-title><source>Ophthalmology</source><year>2011</year><volume>118</volume><fpage>1031</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">21310489</pub-id>
</element-citation></ref><ref id="R11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wiggs</surname><given-names>JL</given-names></name>
<name><surname>Pasquale</surname><given-names>LR</given-names></name></person-group><article-title>Genetics of glaucoma</article-title><source>Hum Mol Genet</source><year>2017</year><volume>26</volume><fpage>R21</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">28505344</pub-id>
</element-citation></ref><ref id="R12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Trivli</surname><given-names>A</given-names></name>
<name><surname>Koliarakis</surname><given-names>I</given-names></name>
<name><surname>Terzidou</surname><given-names>C</given-names></name>
<name><surname>Goulielmos</surname><given-names>GN</given-names></name>
<name><surname>Siganos</surname><given-names>CS</given-names></name>
<name><surname>Spandidos</surname><given-names>DA</given-names></name>
<etal/></person-group><article-title>Normal-tension glaucoma: Pathogenesis and genetics</article-title><source>Exp Ther Med</source><year>2019</year><volume>17</volume><fpage>563</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">30651837</pub-id>
</element-citation></ref><ref id="R13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fan</surname><given-names>BJ</given-names></name>
<name><surname>Wiggs</surname><given-names>JL</given-names></name></person-group><article-title>Glaucoma: Genes, phenotypes, and new directions for therapy</article-title><source>J Clin Invest</source><year>2010</year><volume>120</volume><fpage>3064</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">20811162</pub-id>
</element-citation></ref><ref id="R14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gharahkhani</surname><given-names>P</given-names></name>
<name><surname>Jorgenson</surname><given-names>E</given-names></name>
<name><surname>Hysi</surname><given-names>P</given-names></name>
<name><surname>Khawaja</surname><given-names>AP</given-names></name>
<name><surname>Pendergrass</surname><given-names>S</given-names></name>
<name><surname>Han</surname><given-names>X</given-names></name>
<etal/></person-group><article-title>Genome-wide meta-analysis identifies 127 open-angle glaucoma loci with consistent effect across ancestries</article-title><source>Nat Commun</source><year>2021</year><volume>12</volume><fpage>1258</fpage><pub-id pub-id-type="pmid">33627673</pub-id>
</element-citation></ref><ref id="R15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fox</surname><given-names>AR</given-names></name>
<name><surname>Fingert</surname><given-names>JH</given-names></name></person-group><article-title>Familial normal tension glaucoma genetics</article-title><source>Prog Retin Eye Res</source><year>2023</year><volume>96</volume><fpage>101191</fpage><pub-id pub-id-type="pmid">37353142</pub-id>
</element-citation></ref><ref id="R16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Minegishi</surname><given-names>Y</given-names></name>
<name><surname>Nakayama</surname><given-names>M</given-names></name>
<name><surname>Iejima</surname><given-names>D</given-names></name>
<name><surname>Kawase</surname><given-names>K</given-names></name>
<name><surname>Iwata</surname><given-names>T</given-names></name></person-group><article-title>Significance of optineurin mutations in glaucoma and other diseases</article-title><source>Prog Retin Eye Res</source><year>2016</year><volume>55</volume><fpage>149</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">27693724</pub-id>
</element-citation></ref><ref id="R17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sarfarazi</surname><given-names>M</given-names></name>
<name><surname>Child</surname><given-names>A</given-names></name>
<name><surname>Stoilova</surname><given-names>D</given-names></name>
<name><surname>Brice</surname><given-names>G</given-names></name>
<name><surname>Desai</surname><given-names>T</given-names></name>
<name><surname>Trifan</surname><given-names>OC</given-names></name>
<etal/></person-group><article-title>Localization of the fourth locus (GLC1E) for adult-onset primary open-angle glaucoma to the 10p15-p14 region</article-title><source>Am J Hum Genet</source><year>1998</year><volume>62</volume><fpage>641</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">9497264</pub-id>
</element-citation></ref><ref id="R18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rezaie</surname><given-names>T</given-names></name>
<name><surname>Child</surname><given-names>A</given-names></name>
<name><surname>Hitchings</surname><given-names>R</given-names></name>
<name><surname>Brice</surname><given-names>G</given-names></name>
<name><surname>Miller</surname><given-names>L</given-names></name>
<name><surname>Coca-Prados</surname><given-names>M</given-names></name>
<etal/></person-group><article-title>Adult-onset primary open-angle glaucoma caused by mutations in optineurin</article-title><source>Science</source><year>2002</year><volume>295</volume><fpage>1077</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11834836</pub-id>
</element-citation></ref><ref id="R19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hauser</surname><given-names>MA</given-names></name>
<name><surname>Sena</surname><given-names>DF</given-names></name>
<name><surname>Flor</surname><given-names>J</given-names></name>
<name><surname>Walter</surname><given-names>J</given-names></name>
<name><surname>Auguste</surname><given-names>J</given-names></name>
<name><surname>Larocque-Abramson</surname><given-names>K</given-names></name>
<etal/></person-group><article-title>Distribution of optineurin sequence variations in an ethnically diverse population of low-tension glaucoma patients from the United States</article-title><source>J Glaucoma</source><year>2006</year><volume>15</volume><fpage>358</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">16988596</pub-id>
</element-citation></ref><ref id="R20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aung</surname><given-names>T</given-names></name>
<name><surname>Ebenezer</surname><given-names>ND</given-names></name>
<name><surname>Brice</surname><given-names>G</given-names></name>
<name><surname>Child</surname><given-names>AH</given-names></name>
<name><surname>Prescott</surname><given-names>Q</given-names></name>
<name><surname>Lehmann</surname><given-names>OJ</given-names></name>
<etal/></person-group><article-title>Prevalence of optineurin sequence variants in adult primary open angle glaucoma: Implications for diagnostic testing</article-title><source>J Med Genet</source><year>2003</year><volume>40</volume><fpage>e101</fpage><pub-id pub-id-type="pmid">12920093</pub-id>
</element-citation></ref><ref id="R21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alward</surname><given-names>WLM</given-names></name>
<name><surname>Kwon</surname><given-names>YH</given-names></name>
<name><surname>Kawase</surname><given-names>K</given-names></name>
<name><surname>Craig</surname><given-names>JE</given-names></name>
<name><surname>Hayreh</surname><given-names>SS</given-names></name>
<name><surname>Johnson</surname><given-names>AT</given-names></name>
<etal/></person-group><article-title>Evaluation of optineurin sequence variations in 1,048 patients with open-angle glaucoma</article-title><source>Am J Ophthalmol</source><year>2003</year><volume>136</volume><fpage>904</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">14597044</pub-id>
</element-citation></ref><ref id="R22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Funayama</surname><given-names>T</given-names></name>
<name><surname>Ishikawa</surname><given-names>K</given-names></name>
<name><surname>Ohtake</surname><given-names>Y</given-names></name>
<name><surname>Tanino</surname><given-names>T</given-names></name>
<name><surname>Kurosaka</surname><given-names>D</given-names></name>
<name><surname>Kimura</surname><given-names>I</given-names></name>
<etal/></person-group><article-title>Variants in optineurin gene and their association with tumor necrosis factor-alpha polymorphisms in Japanese patients with glaucoma</article-title><source>Invest Ophthalmol Vis Sci</source><year>2004</year><volume>45</volume><fpage>4359</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">15557444</pub-id>
</element-citation></ref><ref id="R23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tang</surname><given-names>S</given-names></name>
<name><surname>Toda</surname><given-names>Y</given-names></name>
<name><surname>Kashiwagi</surname><given-names>K</given-names></name>
<name><surname>Mabuchi</surname><given-names>F</given-names></name>
<name><surname>Iijima</surname><given-names>H</given-names></name>
<name><surname>Tsukahara</surname><given-names>S</given-names></name>
<etal/></person-group><article-title>The association between Japanese primary open-angle glaucoma and normal tension glaucoma patients and the optineurin gene</article-title><source>Hum Genet</source><year>2003</year><volume>113</volume><fpage>276</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12811537</pub-id>
</element-citation></ref><ref id="R24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Toda</surname><given-names>Y</given-names></name>
<name><surname>Tang</surname><given-names>S</given-names></name>
<name><surname>Kashiwagi</surname><given-names>K</given-names></name>
<name><surname>Mabuchi</surname><given-names>F</given-names></name>
<name><surname>Iijima</surname><given-names>H</given-names></name>
<name><surname>Tsukahara</surname><given-names>S</given-names></name>
<etal/></person-group><article-title>Mutations in the optineurin gene in Japanese patients with primary open-angle glaucoma and normal tension glaucoma</article-title><source>Am J Med Genet A</source><year>2004</year><volume>125A</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">14755458</pub-id>
</element-citation></ref><ref id="R25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fuse</surname><given-names>N</given-names></name>
<name><surname>Takahashi</surname><given-names>K</given-names></name>
<name><surname>Akiyama</surname><given-names>H</given-names></name>
<name><surname>Nakazawa</surname><given-names>T</given-names></name>
<name><surname>Seimiya</surname><given-names>M</given-names></name>
<name><surname>Kuwahara</surname><given-names>S</given-names></name>
<etal/></person-group><article-title>Molecular genetic analysis of optineurin gene for primary open-angle and normal tension glaucoma in the Japanese population</article-title><source>J Glaucoma</source><year>2004</year><volume>13</volume><fpage>299</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">15226658</pub-id>
</element-citation></ref><ref id="R26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Toth</surname><given-names>RP</given-names></name>
<name><surname>Atkin</surname><given-names>JD</given-names></name></person-group><article-title>Dysfunction of optineurin in amyotrophic lateral sclerosis and glaucoma</article-title><source>Front Immunol</source><year>2018</year><volume>9</volume><fpage>1017</fpage><pub-id pub-id-type="pmid">29875767</pub-id>
</element-citation></ref><ref id="R27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goldstein</surname><given-names>O</given-names></name>
<name><surname>Nayshool</surname><given-names>O</given-names></name>
<name><surname>Nefussy</surname><given-names>B</given-names></name>
<name><surname>Traynor</surname><given-names>BJ</given-names></name>
<name><surname>Renton</surname><given-names>AE</given-names></name>
<name><surname>Gana-Weisz</surname><given-names>M</given-names></name>
<etal/></person-group><article-title>OPTN 691_692insAG is a founder mutation causing recessive ALS and increased risk in heterozygotes</article-title><source>Neurology</source><year>2016</year><volume>86</volume><fpage>446</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">26740678</pub-id>
</element-citation></ref><ref id="R28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aung</surname><given-names>T</given-names></name>
<name><surname>Rezaie</surname><given-names>T</given-names></name>
<name><surname>Okada</surname><given-names>K</given-names></name>
<name><surname>Viswanathan</surname><given-names>AC</given-names></name>
<name><surname>Child</surname><given-names>AH</given-names></name>
<name><surname>Brice</surname><given-names>G</given-names></name>
<etal/></person-group><article-title>Clinical features and course of patients with glaucoma with the E50K mutation in the optineurin gene</article-title><source>Invest Ophthalmol Vis Sci</source><year>2005</year><volume>46</volume><fpage>2816</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">16043855</pub-id>
</element-citation></ref><ref id="R29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ayala-Lugo</surname><given-names>RM</given-names></name>
<name><surname>Pawar</surname><given-names>H</given-names></name>
<name><surname>Reed</surname><given-names>DM</given-names></name>
<name><surname>Lichter</surname><given-names>PR</given-names></name>
<name><surname>Moroi</surname><given-names>SE</given-names></name>
<name><surname>Page</surname><given-names>M</given-names></name>
<etal/></person-group><article-title>Variation in optineurin (OPTN) allele frequencies between and within populations</article-title><source>Mol Vis</source><year>2007</year><volume>13</volume><fpage>151</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">17293779</pub-id>
</element-citation></ref><ref id="R30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Minegishi</surname><given-names>Y</given-names></name>
<name><surname>Iejima</surname><given-names>D</given-names></name>
<name><surname>Kobayashi</surname><given-names>H</given-names></name>
<name><surname>Chi</surname><given-names>ZL</given-names></name>
<name><surname>Kawase</surname><given-names>K</given-names></name>
<name><surname>Yamamoto</surname><given-names>T</given-names></name>
<etal/></person-group><article-title>Enhanced optineurin E50K-TBK1 interaction evokes protein insolubility and initiates familial primary open-angle glaucoma</article-title><source>Hum Mol Genet</source><year>2013</year><volume>22</volume><fpage>3559</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">23669351</pub-id>
</element-citation></ref><ref id="R31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qiu</surname><given-names>Y</given-names></name>
<name><surname>Wang</surname><given-names>J</given-names></name>
<name><surname>Li</surname><given-names>H</given-names></name>
<name><surname>Yang</surname><given-names>B</given-names></name>
<name><surname>Wang</surname><given-names>J</given-names></name>
<name><surname>He</surname><given-names>Q</given-names></name>
<etal/></person-group><article-title>Emerging views of OPTN (optineurin) function in the autophagic process associated with disease</article-title><source>Autophagy</source><year>2022</year><volume>18</volume><fpage>73</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">33783320</pub-id>
</element-citation></ref><ref id="R32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Richter</surname><given-names>B</given-names></name>
<name><surname>Sliter</surname><given-names>DA</given-names></name>
<name><surname>Herhaus</surname><given-names>L</given-names></name>
<name><surname>Stolz</surname><given-names>A</given-names></name>
<name><surname>Wang</surname><given-names>C</given-names></name>
<name><surname>Beli</surname><given-names>P</given-names></name>
<etal/></person-group><article-title>Phosphorylation of OPTN by TBK1 enhances its binding to Ub chains and promotes selective autophagy of damaged mitochondria</article-title><source>Proc Natl Acad Sci U S A</source><year>2016</year><volume>113</volume><fpage>4039</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">27035970</pub-id>
</element-citation></ref><ref id="R33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wild</surname><given-names>P</given-names></name>
<name><surname>Farhan</surname><given-names>H</given-names></name>
<name><surname>McEwan</surname><given-names>DG</given-names></name>
<name><surname>Wagner</surname><given-names>S</given-names></name>
<name><surname>Rogov</surname><given-names>VV</given-names></name>
<name><surname>Brady</surname><given-names>NR</given-names></name>
<etal/></person-group><article-title>Phosphorylation of the autophagy receptor optineurin restricts Salmonella growth</article-title><source>Science</source><year>2011</year><volume>333</volume><fpage>228</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">21617041</pub-id>
</element-citation></ref><ref id="R34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moore</surname><given-names>AS</given-names></name>
<name><surname>Holzbaur</surname><given-names>ELF</given-names></name></person-group><article-title>Spatiotemporal dynamics of autophagy receptors in selective mitophagy</article-title><source>Autophagy</source><year>2016</year><volume>12</volume><fpage>1956</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">27484150</pub-id>
</element-citation></ref><ref id="R35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Korac</surname><given-names>J</given-names></name>
<name><surname>Schaeffer</surname><given-names>V</given-names></name>
<name><surname>Kovacevic</surname><given-names>I</given-names></name>
<name><surname>Clement</surname><given-names>AM</given-names></name>
<name><surname>Jungblut</surname><given-names>B</given-names></name>
<name><surname>Behl</surname><given-names>C</given-names></name>
<etal/></person-group><article-title>Ubiquitin-independent function of optineurin in autophagic clearance of protein aggregates</article-title><source>J Cell Sci</source><year>2013</year><volume>126</volume><fpage>580</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">23178947</pub-id>
</element-citation></ref><ref id="R36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sundaramoorthy</surname><given-names>V</given-names></name>
<name><surname>Walker</surname><given-names>AK</given-names></name>
<name><surname>Tan</surname><given-names>V</given-names></name>
<name><surname>Fifita</surname><given-names>JA</given-names></name>
<name><surname>Mccann</surname><given-names>EP</given-names></name>
<name><surname>Williams</surname><given-names>KL</given-names></name>
<etal/></person-group><article-title>Defects in optineurin- and myosin VI-mediated cellular trafficking in amyotrophic lateral sclerosis</article-title><source>Hum Mol Genet</source><year>2015</year><volume>24</volume><fpage>3830</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">25859013</pub-id>
</element-citation></ref><ref id="R37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sahlender</surname><given-names>DA</given-names></name>
<name><surname>Roberts</surname><given-names>RC</given-names></name>
<name><surname>Arden</surname><given-names>SD</given-names></name>
<name><surname>Spudich</surname><given-names>G</given-names></name>
<name><surname>Taylor</surname><given-names>MJ</given-names></name>
<name><surname>Luzio</surname><given-names>JP</given-names></name>
<etal/></person-group><article-title>Optineurin links myosin VI to the Golgi complex and is involved in Golgi organization and exocytosis</article-title><source>J Cell Biol</source><year>2005</year><volume>169</volume><fpage>285</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">15837803</pub-id>
</element-citation></ref><ref id="R38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sippl</surname><given-names>C</given-names></name>
<name><surname>Bosserhoff</surname><given-names>AK</given-names></name>
<name><surname>Fischer</surname><given-names>D</given-names></name>
<name><surname>Tamm</surname><given-names>ER</given-names></name></person-group><article-title>Depletion of optineurin in RGC-5 cells derived from retinal neurons causes apoptosis and reduces the secretion of neurotrophins</article-title><source>Exp Eye Res</source><year>2011</year><volume>93</volume><fpage>669</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">21896272</pub-id>
</element-citation></ref><ref id="R39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nagabhushana</surname><given-names>A</given-names></name>
<name><surname>Chalasani</surname><given-names>ML</given-names></name>
<name><surname>Jain</surname><given-names>N</given-names></name>
<name><surname>Radha</surname><given-names>V</given-names></name>
<name><surname>Rangaraj</surname><given-names>N</given-names></name>
<name><surname>Balasubramanian</surname><given-names>D</given-names></name>
<etal/></person-group><article-title>Regulation of endocytic trafficking of transferrin receptor by optineurin and its impairment by a glaucoma-associated mutant</article-title><source>BMC Cell Biol</source><year>2010</year><volume>11</volume><fpage>4</fpage><pub-id pub-id-type="pmid">20085643</pub-id>
</element-citation></ref><ref id="R40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Park</surname><given-names>B</given-names></name>
<name><surname>Ying</surname><given-names>H</given-names></name>
<name><surname>Shen</surname><given-names>X</given-names></name>
<name><surname>Park</surname><given-names>JS</given-names></name>
<name><surname>Qiu</surname><given-names>Y</given-names></name>
<name><surname>Shyam</surname><given-names>R</given-names></name>
<etal/></person-group><article-title>Impairment of protein trafficking upon overexpression and mutation of optineurin</article-title><source>PLoS One</source><year>2010</year><volume>5</volume><fpage>e11547</fpage><pub-id pub-id-type="pmid">20634958</pub-id>
</element-citation></ref><ref id="R41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Y</given-names></name>
<name><surname>Kang</surname><given-names>J</given-names></name>
<name><surname>Horwitz</surname><given-names>MS</given-names></name></person-group><article-title>Interaction of an adenovirus E3 14.7-kilodalton protein with a novel tumor necrosis factor alpha-inducible cellular protein containing leucine zipper domains</article-title><source>Mol Cell Biol</source><year>1998</year><volume>18</volume><fpage>1601</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">9488477</pub-id>
</element-citation></ref><ref id="R42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sayyad</surname><given-names>Z</given-names></name>
<name><surname>Sirohi</surname><given-names>K</given-names></name>
<name><surname>Radha</surname><given-names>V</given-names></name>
<name><surname>Swarup</surname><given-names>G</given-names></name></person-group><article-title>661W is a retinal ganglion precursor-like cell line in which glaucoma-associated optineurin mutants induce cell death selectively</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><fpage>16855</fpage><pub-id pub-id-type="pmid">29203899</pub-id>
</element-citation></ref><ref id="R43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chalasani</surname><given-names>ML</given-names></name>
<name><surname>Radha</surname><given-names>V</given-names></name>
<name><surname>Gupta</surname><given-names>V</given-names></name>
<name><surname>Agarwal</surname><given-names>N</given-names></name>
<name><surname>Balasubramanian</surname><given-names>D</given-names></name>
<name><surname>Swarup</surname><given-names>G</given-names></name></person-group><article-title>A glaucoma-associated mutant of optineurin selectively induces death of retinal ganglion cells which is inhibited by antioxidants</article-title><source>Invest Ophthalmol Vis Sci</source><year>2007</year><volume>48</volume><fpage>1607</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">17389490</pub-id>
</element-citation></ref><ref id="R44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sayyad</surname><given-names>Z</given-names></name>
<name><surname>Vishwakarma</surname><given-names>S</given-names></name>
<name><surname>Dave</surname><given-names>TV</given-names></name>
<name><surname>Naik</surname><given-names>MN</given-names></name>
<name><surname>Radha</surname><given-names>V</given-names></name>
<name><surname>Kaur</surname><given-names>I</given-names></name>
<etal/></person-group><article-title>Human primary retinal cells as an in-vitro model for investigating defective signalling caused by OPTN mutants associated with glaucoma</article-title><source>Neurochem Int</source><year>2021</year><volume>148</volume><fpage>105075</fpage><pub-id pub-id-type="pmid">34023378</pub-id>
</element-citation></ref><ref id="R45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>VanderWall</surname><given-names>KB</given-names></name>
<name><surname>Huang</surname><given-names>KC</given-names></name>
<name><surname>Pan</surname><given-names>Y</given-names></name>
<name><surname>Lavekar</surname><given-names>SS</given-names></name>
<name><surname>Fligor</surname><given-names>CM</given-names></name>
<name><surname>Allsop</surname><given-names>AR</given-names></name>
<etal/></person-group><article-title>Retinal ganglion cells with a glaucoma OPTN(E50K) mutation exhibit neurodegenerative phenotypes when derived from three-dimensional retinal organoids</article-title><source>Stem Cell Reports</source><year>2020</year><volume>15</volume><fpage>52</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">32531194</pub-id>
</element-citation></ref><ref id="R46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gomes</surname><given-names>C</given-names></name>
<name><surname>VanderWall</surname><given-names>KB</given-names></name>
<name><surname>Pan</surname><given-names>Y</given-names></name>
<name><surname>Lu</surname><given-names>X</given-names></name>
<name><surname>Lavekar</surname><given-names>SS</given-names></name>
<name><surname>Huang</surname><given-names>KC</given-names></name>
<etal/></person-group><article-title>Astrocytes modulate neurodegenerative phenotypes associated with glaucoma in OPTN(E50K) human stem cell-derived retinal ganglion cells</article-title><source>Stem Cell Reports</source><year>2022</year><volume>17</volume><fpage>1636</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">35714595</pub-id>
</element-citation></ref><ref id="R47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chi</surname><given-names>ZL</given-names></name>
<name><surname>Akahori</surname><given-names>M</given-names></name>
<name><surname>Obazawa</surname><given-names>M</given-names></name>
<name><surname>Minami</surname><given-names>M</given-names></name>
<name><surname>Noda</surname><given-names>T</given-names></name>
<name><surname>Nakaya</surname><given-names>N</given-names></name>
<etal/></person-group><article-title>Overexpression of optineurin E50K disrupts Rab8 interaction and leads to a progressive retinal degeneration in mice</article-title><source>Hum Mol Genet</source><year>2010</year><volume>19</volume><fpage>2606</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">20388642</pub-id>
</element-citation></ref><ref id="R48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meng</surname><given-names>Q</given-names></name>
<name><surname>Xiao</surname><given-names>Z</given-names></name>
<name><surname>Yuan</surname><given-names>H</given-names></name>
<name><surname>Xue</surname><given-names>F</given-names></name>
<name><surname>Zhu</surname><given-names>Y</given-names></name>
<name><surname>Zhou</surname><given-names>X</given-names></name>
<etal/></person-group><article-title>Transgenic mice with overexpression of mutated human optineurin(E50K) in the retina</article-title><source>Mol Biol Rep</source><year>2012</year><volume>39</volume><fpage>1119</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">21681420</pub-id>
</element-citation></ref><ref id="R49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tseng</surname><given-names>HC</given-names></name>
<name><surname>Riday</surname><given-names>TT</given-names></name>
<name><surname>McKee</surname><given-names>C</given-names></name>
<name><surname>Braine</surname><given-names>CE</given-names></name>
<name><surname>Bomze</surname><given-names>H</given-names></name>
<name><surname>Barak</surname><given-names>I</given-names></name>
<etal/></person-group><article-title>Visual impairment in an optineurin mouse model of primary open-angle glaucoma</article-title><source>Neurobiol Aging</source><year>2015</year><volume>36</volume><fpage>2201</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">25818176</pub-id>
</element-citation></ref><ref id="R50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hou</surname><given-names>M</given-names></name>
<name><surname>Shao</surname><given-names>Z</given-names></name>
<name><surname>Zhang</surname><given-names>S</given-names></name>
<name><surname>Liu</surname><given-names>X</given-names></name>
<name><surname>Fan</surname><given-names>P</given-names></name>
<name><surname>Jiang</surname><given-names>M</given-names></name>
<etal/></person-group><article-title>Age-related visual impairments and retinal ganglion cells axonal degeneration in a mouse model harboring OPTN (E50K) mutation</article-title><source>Cell Death Dis</source><year>2022</year><volume>13</volume><fpage>362</fpage><pub-id pub-id-type="pmid">35436991</pub-id>
</element-citation></ref><ref id="R51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Revach</surname><given-names>OY</given-names></name>
<name><surname>Liu</surname><given-names>S</given-names></name>
<name><surname>Jenkins</surname><given-names>RW</given-names></name></person-group><article-title>Targeting TANK-binding kinase 1 (TBK1) in cancer</article-title><source>Expert Opin Ther Targets</source><year>2020</year><volume>24</volume><fpage>1065</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">32962465</pub-id>
</element-citation></ref><ref id="R52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Runde</surname><given-names>AP</given-names></name>
<name><surname>Mack</surname><given-names>R</given-names></name>
<name><surname>S</surname><given-names>J PB</given-names></name>
<name><surname>Zhang</surname><given-names>J</given-names></name></person-group><article-title>The role of TBK1 in cancer pathogenesis and anticancer immunity</article-title><source>J Exp Clin Cancer Res</source><year>2022</year><volume>41</volume><fpage>135</fpage><pub-id pub-id-type="pmid">35395857</pub-id>
</element-citation></ref><ref id="R53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fingert</surname><given-names>JH</given-names></name>
<name><surname>Robin</surname><given-names>AL</given-names></name>
<name><surname>Stone</surname><given-names>JL</given-names></name>
<name><surname>Roos</surname><given-names>BR</given-names></name>
<name><surname>Davis</surname><given-names>LK</given-names></name>
<name><surname>Scheetz</surname><given-names>TE</given-names></name>
<etal/></person-group><article-title>Copy number variations on chromosome 12q14 in patients with normal tension glaucoma</article-title><source>Hum Mol Genet</source><year>2011</year><volume>20</volume><fpage>2482</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">21447600</pub-id>
</element-citation></ref><ref id="R54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kawase</surname><given-names>K</given-names></name>
<name><surname>Allingham</surname><given-names>RR</given-names></name>
<name><surname>Meguro</surname><given-names>A</given-names></name>
<name><surname>Mizuki</surname><given-names>N</given-names></name>
<name><surname>Roos</surname><given-names>B</given-names></name>
<name><surname>Solivan-Timpe</surname><given-names>FM</given-names></name>
<etal/></person-group><article-title>Confirmation of TBK1 duplication in normal tension glaucoma</article-title><source>Exp Eye Res</source><year>2012</year><volume>96</volume><fpage>178</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">22306015</pub-id>
</element-citation></ref><ref id="R55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>DeLuca</surname><given-names>AP</given-names></name>
<name><surname>Alward</surname><given-names>WLM</given-names></name>
<name><surname>Liebmann</surname><given-names>J</given-names></name>
<name><surname>Ritch</surname><given-names>R</given-names></name>
<name><surname>Kawase</surname><given-names>K</given-names></name>
<name><surname>Kwon</surname><given-names>YH</given-names></name>
<etal/></person-group><article-title>Genomic organization of TBK1 copy number variations in glaucoma patients</article-title><source>J Glaucoma</source><year>2017</year><volume>26</volume><fpage>1063</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">28984711</pub-id>
</element-citation></ref><ref id="R56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Awadalla</surname><given-names>MS</given-names></name>
<name><surname>Fingert</surname><given-names>JH</given-names></name>
<name><surname>Roos</surname><given-names>BE</given-names></name>
<name><surname>Chen</surname><given-names>S</given-names></name>
<name><surname>Holmes</surname><given-names>R</given-names></name>
<name><surname>Graham</surname><given-names>SL</given-names></name>
<etal/></person-group><article-title>Copy number variations of TBK1 in Australian patients with primary open-angle glaucoma</article-title><source>Am J Ophthalmol</source><year>2015</year><volume>159</volume><fpage>124</fpage><lpage>30.e1</lpage><pub-id pub-id-type="pmid">25284765</pub-id>
</element-citation></ref><ref id="R57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>MJ</given-names></name>
<name><surname>Kim</surname><given-names>YW</given-names></name>
<name><surname>Jeoung</surname><given-names>JW</given-names></name>
<name><surname>Seong</surname><given-names>MW</given-names></name>
<name><surname>Lee</surname><given-names>JS</given-names></name>
<name><surname>Kim</surname><given-names>DM</given-names></name>
<etal/></person-group><article-title>Genomic characterization of TBK1 duplication in Korean normal-tension glaucoma patients</article-title><source>J Glaucoma</source><year>2020</year><volume>29</volume><fpage>331</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">32079994</pub-id>
</element-citation></ref><ref id="R58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ritch</surname><given-names>R</given-names></name>
<name><surname>Darbro</surname><given-names>B</given-names></name>
<name><surname>Menon</surname><given-names>G</given-names></name>
<name><surname>Khanna</surname><given-names>CL</given-names></name>
<name><surname>Solivan-Timpe</surname><given-names>F</given-names></name>
<name><surname>Roos</surname><given-names>BR</given-names></name>
<etal/></person-group><article-title>TBK1 gene duplication and normal-tension glaucoma</article-title><source>JAMA Ophthalmol</source><year>2014</year><volume>132</volume><fpage>544</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">24699864</pub-id>
</element-citation></ref><ref id="R59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaurani</surname><given-names>L</given-names></name>
<name><surname>Vishal</surname><given-names>M</given-names></name>
<name><surname>Ray</surname><given-names>J</given-names></name>
<name><surname>Sen</surname><given-names>A</given-names></name>
<name><surname>Ray</surname><given-names>K</given-names></name>
<name><surname>Mukhopadhyay</surname><given-names>A</given-names></name></person-group><article-title>TBK1 duplication is found in normal tension and not in high tension glaucoma patients of Indian origin</article-title><source>J Genet</source><year>2016</year><volume>95</volume><fpage>459</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">27350692</pub-id>
</element-citation></ref><ref id="R60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ahmad</surname><given-names>L</given-names></name>
<name><surname>Zhang</surname><given-names>SY</given-names></name>
<name><surname>Casanova</surname><given-names>JL</given-names></name>
<name><surname>Sancho-Shimizu</surname><given-names>V</given-names></name></person-group><article-title>Human TBK1: A gatekeeper of neuroinflammation</article-title><source>Trends Mol Med</source><year>2016</year><volume>22</volume><fpage>511</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">27211305</pub-id>
</element-citation></ref><ref id="R61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tucker</surname><given-names>BA</given-names></name>
<name><surname>Solivan-Timpe</surname><given-names>F</given-names></name>
<name><surname>Roos</surname><given-names>BR</given-names></name>
<name><surname>Anfinson</surname><given-names>KR</given-names></name>
<name><surname>Robin</surname><given-names>AL</given-names></name>
<name><surname>Wiley</surname><given-names>LA</given-names></name>
<etal/></person-group><article-title>Duplication of TBK1 stimulates autophagy in iPSC-derived retinal cells from a patient with normal tension glaucoma</article-title><source>J Stem Cell Res Ther</source><year>2014</year><volume>3</volume><fpage>161</fpage><pub-id pub-id-type="pmid">24883232</pub-id>
</element-citation></ref><ref id="R62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fingert</surname><given-names>JH</given-names></name>
<name><surname>Miller</surname><given-names>K</given-names></name>
<name><surname>Hedberg-Buenz</surname><given-names>A</given-names></name>
<name><surname>Roos</surname><given-names>BR</given-names></name>
<name><surname>Lewis</surname><given-names>CJ</given-names></name>
<name><surname>Mullins</surname><given-names>RF</given-names></name>
<etal/></person-group><article-title>Transgenic TBK1 mice have features of normal tension glaucoma</article-title><source>Hum Mol Genet</source><year>2017</year><volume>26</volume><fpage>124</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">28025332</pub-id>
</element-citation></ref><ref id="R63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smaili</surname><given-names>W</given-names></name>
<name><surname>Elalaoui</surname><given-names>SC</given-names></name>
<name><surname>Zrhidri</surname><given-names>A</given-names></name>
<name><surname>Raymond</surname><given-names>L</given-names></name>
<name><surname>Eg&#x000e9;a</surname><given-names>G</given-names></name>
<name><surname>Taoudi</surname><given-names>M</given-names></name>
<etal/></person-group><article-title>Exome sequencing revealed a novel homozygous METTL23 gene mutation leading to familial mild intellectual disability with dysmorphic features</article-title><source>Eur J Med Genet</source><year>2020</year><volume>63</volume><fpage>103951</fpage><pub-id pub-id-type="pmid">32439618</pub-id>
</element-citation></ref><ref id="R64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hatanaka</surname><given-names>Y</given-names></name>
<name><surname>Tsusaka</surname><given-names>T</given-names></name>
<name><surname>Shimizu</surname><given-names>N</given-names></name>
<name><surname>Morita</surname><given-names>K</given-names></name>
<name><surname>Suzuki</surname><given-names>T</given-names></name>
<name><surname>Machida</surname><given-names>S</given-names></name>
<etal/></person-group><article-title>Histone H3 methylated at arginine 17 is essential for reprogramming the paternal genome in zygotes</article-title><source>Cell Rep</source><year>2017</year><volume>20</volume><fpage>2756</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">28930672</pub-id>
</element-citation></ref><ref id="R65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Feng</surname><given-names>L</given-names></name>
<name><surname>Wang</surname><given-names>C</given-names></name>
<name><surname>Zhang</surname><given-names>C</given-names></name>
<name><surname>Zhang</surname><given-names>W</given-names></name>
<name><surname>Song</surname><given-names>W</given-names></name></person-group><article-title>Role of epigenetic regulation in glaucoma</article-title><source>Biomed Pharmacother</source><year>2023</year><volume>168</volume><fpage>115633</fpage><pub-id pub-id-type="pmid">37806089</pub-id>
</element-citation></ref><ref id="R66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Soutto</surname><given-names>M</given-names></name>
<name><surname>Belkhiri</surname><given-names>A</given-names></name>
<name><surname>Piazuelo</surname><given-names>MB</given-names></name>
<name><surname>Schneider</surname><given-names>BG</given-names></name>
<name><surname>Peng</surname><given-names>D</given-names></name>
<name><surname>Jiang</surname><given-names>A</given-names></name>
<etal/></person-group><article-title>Loss of TFF1 is associated with activation of NF-&#x003ba;B-mediated inflammation and gastric neoplasia in mice and humans</article-title><source>J Clin Invest</source><year>2011</year><volume>121</volume><fpage>1753</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">21490402</pub-id>
</element-citation></ref><ref id="R67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>T</given-names></name>
<name><surname>Zhang</surname><given-names>L</given-names></name>
<name><surname>Joo</surname><given-names>D</given-names></name>
<name><surname>Sun</surname><given-names>SC</given-names></name></person-group><article-title>NF-&#x003ba;B signaling in inflammation</article-title><source>Signal Transduct Target Ther</source><year>2017</year><volume>2</volume><fpage>17023</fpage><pub-id pub-id-type="pmid">29158945</pub-id>
</element-citation></ref><ref id="R68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chi</surname><given-names>W</given-names></name>
<name><surname>Li</surname><given-names>F</given-names></name>
<name><surname>Chen</surname><given-names>H</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
<name><surname>Zhu</surname><given-names>Y</given-names></name>
<name><surname>Yang</surname><given-names>X</given-names></name>
<etal/></person-group><article-title>Caspase-8 promotes NLRP1/NLRP3 inflammasome activation and IL-1&#x003b2; production in acute glaucoma</article-title><source>Proc Natl Acad Sci U S A</source><year>2014</year><volume>111</volume><fpage>11181</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">25024200</pub-id>
</element-citation></ref><ref id="R69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sivakumar</surname><given-names>V</given-names></name>
<name><surname>Foulds</surname><given-names>WS</given-names></name>
<name><surname>Luu</surname><given-names>CD</given-names></name>
<name><surname>Ling</surname><given-names>EA</given-names></name>
<name><surname>Kaur</surname><given-names>C</given-names></name></person-group><article-title>Retinal ganglion cell death is induced by microglia derived pro-inflammatory cytokines in the hypoxic neonatal retina</article-title><source>J Pathol</source><year>2011</year><volume>224</volume><fpage>245</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">21404274</pub-id>
</element-citation></ref><ref id="R70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sharma</surname><given-names>R</given-names></name>
<name><surname>Grover</surname><given-names>A</given-names></name></person-group><article-title>Myocilin-associated glaucoma: A historical perspective and recent research progress</article-title><source>Mol Vis</source><year>2021</year><volume>27</volume><fpage>480</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">34497454</pub-id>
</element-citation></ref><ref id="R71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stone</surname><given-names>EM</given-names></name>
<name><surname>Fingert</surname><given-names>JH</given-names></name>
<name><surname>Alward</surname><given-names>WL</given-names></name>
<name><surname>Nguyen</surname><given-names>TD</given-names></name>
<name><surname>Polansky</surname><given-names>JR</given-names></name>
<name><surname>Sunden</surname><given-names>SL</given-names></name>
<etal/></person-group><article-title>Identification of a gene that causes primary open angle glaucoma</article-title><source>Science</source><year>1997</year><volume>275</volume><fpage>668</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">9005853</pub-id>
</element-citation></ref><ref id="R72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Y</given-names></name>
<name><surname>Allingham</surname><given-names>RR</given-names></name></person-group><article-title>Major review: Molecular genetics of primary open-angle glaucoma</article-title><source>Exp Eye Res</source><year>2017</year><volume>160</volume><fpage>62</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">28499933</pub-id>
</element-citation></ref><ref id="R73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Trivli</surname><given-names>A</given-names></name>
<name><surname>Zervou</surname><given-names>MI</given-names></name>
<name><surname>Goulielmos</surname><given-names>GN</given-names></name>
<name><surname>Spandidos</surname><given-names>DA</given-names></name>
<name><surname>Detorakis</surname><given-names>ET</given-names></name></person-group><article-title>Primary open angle glaucoma genetics: The common variants and their clinical associations (Review)</article-title><source>Mol Med Rep</source><year>2020</year><volume>22</volume><fpage>1103</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">32626970</pub-id>
</element-citation></ref><ref id="R74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mardin</surname><given-names>CY</given-names></name>
<name><surname>Velten</surname><given-names>I</given-names></name>
<name><surname>Ozbey</surname><given-names>S</given-names></name>
<name><surname>Rautenstrauss</surname><given-names>B</given-names></name>
<name><surname>Michels-Rautenstrauss</surname><given-names>K</given-names></name></person-group><article-title>A GLC1A gene Gln368Stop mutation in a patient with normal-tension open-angle glaucoma</article-title><source>J Glaucoma</source><year>1999</year><volume>8</volume><fpage>154</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">10209734</pub-id>
</element-citation></ref><ref id="R75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Michels-Rautenstrauss</surname><given-names>K</given-names></name>
<name><surname>Mardin</surname><given-names>C</given-names></name>
<name><surname>Wakili</surname><given-names>N</given-names></name>
<name><surname>J&#x000fc;nemann</surname><given-names>AM</given-names></name>
<name><surname>Villalobos</surname><given-names>L</given-names></name>
<name><surname>Mejia</surname><given-names>C</given-names></name>
<etal/></person-group><article-title>Novel mutations in the MYOC/GLC1A gene in a large group of glaucoma patients</article-title><source>Hum Mutat</source><year>2002</year><volume>20</volume><fpage>479</fpage><lpage>80</lpage></element-citation></ref><ref id="R76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alward</surname><given-names>WLM</given-names></name>
<name><surname>Kwon</surname><given-names>YH</given-names></name>
<name><surname>Khanna</surname><given-names>CL</given-names></name>
<name><surname>Johnson</surname><given-names>AT</given-names></name>
<name><surname>Hayreh</surname><given-names>SS</given-names></name>
<name><surname>Zimmerman</surname><given-names>MB</given-names></name>
<etal/></person-group><article-title>Variations in the myocilin gene in patients with open-angle glaucoma</article-title><source>Arch Ophthalmol</source><year>2002</year><volume>120</volume><fpage>1189</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">12215093</pub-id>
</element-citation></ref><ref id="R77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alward</surname><given-names>WLM</given-names></name>
<name><surname>van der Heide</surname><given-names>C</given-names></name>
<name><surname>Khanna</surname><given-names>CL</given-names></name>
<name><surname>Roos</surname><given-names>BR</given-names></name>
<name><surname>Sivaprasad</surname><given-names>S</given-names></name>
<name><surname>Kam</surname><given-names>J</given-names></name>
<etal/></person-group><article-title>Myocilin mutations in patients with normal-tension glaucoma</article-title><source>JAMA Ophthalmol</source><year>2019</year><volume>137</volume><fpage>559</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">30816940</pub-id>
</element-citation></ref><ref id="R78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liuska</surname><given-names>PJ</given-names></name>
<name><surname>Lemmel&#x000e4;</surname><given-names>S</given-names></name>
<name><surname>Havulinna</surname><given-names>AS</given-names></name>
<name><surname>Kaarniranta</surname><given-names>K</given-names></name>
<name><surname>Uusitalo</surname><given-names>H</given-names></name>
<name><surname>Laivuori</surname><given-names>H</given-names></name>
<etal/></person-group><article-title>Association of the MYOC p.(Gln368Ter) variant with glaucoma in a Finnish population</article-title><source>JAMA Ophthalmol</source><year>2021</year><volume>139</volume><fpage>762</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">34081096</pub-id>
</element-citation></ref><ref id="R79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fingert</surname><given-names>JH</given-names></name>
<name><surname>H&#x000e9;on</surname><given-names>E</given-names></name>
<name><surname>Liebmann</surname><given-names>JM</given-names></name>
<name><surname>Yamamoto</surname><given-names>T</given-names></name>
<name><surname>Craig</surname><given-names>JE</given-names></name>
<name><surname>Rait</surname><given-names>J</given-names></name>
<etal/></person-group><article-title>Analysis of myocilin mutations in 1703 glaucoma patients from five different populations</article-title><source>Hum Mol Genet</source><year>1999</year><volume>8</volume><fpage>899</fpage><lpage>905</lpage><pub-id pub-id-type="pmid">10196380</pub-id>
</element-citation></ref><ref id="R80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fernandes</surname><given-names>KA</given-names></name>
<name><surname>Harder</surname><given-names>JM</given-names></name>
<name><surname>Williams</surname><given-names>PA</given-names></name>
<name><surname>Rausch</surname><given-names>RL</given-names></name>
<name><surname>Kiernan</surname><given-names>AE</given-names></name>
<name><surname>Nair</surname><given-names>KS</given-names></name>
<etal/></person-group><article-title>Using genetic mouse models to gain insight into glaucoma: Past results and future possibilities</article-title><source>Exp Eye Res</source><year>2015</year><volume>141</volume><fpage>42</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">26116903</pub-id>
</element-citation></ref><ref id="R81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tamm</surname><given-names>ER</given-names></name></person-group><article-title>Myocilin and glaucoma: Facts and ideas</article-title><source>Prog Retin Eye Res</source><year>2002</year><volume>21</volume><fpage>395</fpage><lpage>428</lpage><pub-id pub-id-type="pmid">12150989</pub-id>
</element-citation></ref><ref id="R82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Polansky</surname><given-names>JR</given-names></name>
<name><surname>Fauss</surname><given-names>DJ</given-names></name>
<name><surname>Chen</surname><given-names>P</given-names></name>
<name><surname>Chen</surname><given-names>H</given-names></name>
<name><surname>L&#x000fc;tjen-Drecoll</surname><given-names>E</given-names></name>
<name><surname>Johnson</surname><given-names>D</given-names></name>
<etal/></person-group><article-title>Cellular pharmacology and molecular biology of the trabecular meshwork inducible glucocorticoid response gene product</article-title><source>Ophthalmologica</source><year>1997</year><volume>211</volume><fpage>126</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">9176893</pub-id>
</element-citation></ref><ref id="R83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jacobson</surname><given-names>N</given-names></name>
<name><surname>Andrews</surname><given-names>M</given-names></name>
<name><surname>Shepard</surname><given-names>AR</given-names></name>
<name><surname>Nishimura</surname><given-names>D</given-names></name>
<name><surname>Searby</surname><given-names>C</given-names></name>
<name><surname>Fingert</surname><given-names>JH</given-names></name>
<etal/></person-group><article-title>Non-secretion of mutant proteins of the glaucoma gene myocilin in cultured trabecular meshwork cells and in aqueous humor</article-title><source>Hum Mol Genet</source><year>2001</year><volume>10</volume><fpage>117</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">11152659</pub-id>
</element-citation></ref><ref id="R84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>BS</given-names></name>
<name><surname>Savinova</surname><given-names>OV</given-names></name>
<name><surname>Reedy</surname><given-names>MV</given-names></name>
<name><surname>Martin</surname><given-names>J</given-names></name>
<name><surname>Lun</surname><given-names>Y</given-names></name>
<name><surname>Gan</surname><given-names>L</given-names></name>
<etal/></person-group><article-title>Targeted disruption of the myocilin gene (Myoc) suggests that human glaucoma-causing mutations are gain of function</article-title><source>Mol Cell Biol</source><year>2001</year><volume>21</volume><fpage>7707</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">11604506</pub-id>
</element-citation></ref><ref id="R85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pang</surname><given-names>CP</given-names></name>
<name><surname>Lam</surname><given-names>DSC</given-names></name></person-group><article-title>Differential occurrence of mutations causative of eye diseases in the Chinese population</article-title><source>Hum Mutat</source><year>2002</year><volume>19</volume><fpage>189</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">11857735</pub-id>
</element-citation></ref><ref id="R86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gould</surname><given-names>DB</given-names></name>
<name><surname>Miceli-Libby</surname><given-names>L</given-names></name>
<name><surname>Savinova</surname><given-names>OV</given-names></name>
<name><surname>Torrado</surname><given-names>M</given-names></name>
<name><surname>Tomarev</surname><given-names>SI</given-names></name>
<name><surname>Smith</surname><given-names>RS</given-names></name>
<etal/></person-group><article-title>Genetically increasing Myoc expression supports a necessary pathologic role of abnormal proteins in glaucoma</article-title><source>Mol Cell Biol</source><year>2004</year><volume>24</volume><fpage>9019</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">15456875</pub-id>
</element-citation></ref><ref id="R87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Resch</surname><given-names>ZT</given-names></name>
<name><surname>Fautsch</surname><given-names>MP</given-names></name></person-group><article-title>Glaucoma-associated myocilin: A better understanding but much more to learn</article-title><source>Exp Eye Res</source><year>2009</year><volume>88</volume><fpage>704</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">18804106</pub-id>
</element-citation></ref><ref id="R88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shepard</surname><given-names>AR</given-names></name>
<name><surname>Jacobson</surname><given-names>N</given-names></name>
<name><surname>Millar</surname><given-names>JC</given-names></name>
<name><surname>Pang</surname><given-names>IH</given-names></name>
<name><surname>Steely</surname><given-names>HT</given-names></name>
<name><surname>Searby</surname><given-names>CC</given-names></name>
<etal/></person-group><article-title>Glaucoma-causing myocilin mutants require the Peroxisomal targeting signal-1 receptor (PTS1R) to elevate intraocular pressure</article-title><source>Hum Mol Genet</source><year>2007</year><volume>16</volume><fpage>609</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">17317787</pub-id>
</element-citation></ref><ref id="R89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Elden</surname><given-names>AC</given-names></name>
<name><surname>Kim</surname><given-names>HJ</given-names></name>
<name><surname>Hart</surname><given-names>MP</given-names></name>
<name><surname>Chen-Plotkin</surname><given-names>AS</given-names></name>
<name><surname>Johnson</surname><given-names>BS</given-names></name>
<name><surname>Fang</surname><given-names>X</given-names></name>
<etal/></person-group><article-title>Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS</article-title><source>Nature</source><year>2010</year><volume>466</volume><fpage>1069</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">20740007</pub-id>
</element-citation></ref><ref id="R90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bailey</surname><given-names>JNC</given-names></name>
<name><surname>Loomis</surname><given-names>SJ</given-names></name>
<name><surname>Kang</surname><given-names>JH</given-names></name>
<name><surname>Allingham</surname><given-names>RR</given-names></name>
<name><surname>Gharahkhani</surname><given-names>P</given-names></name>
<name><surname>Khor</surname><given-names>CC</given-names></name>
<etal/></person-group><article-title>Genome-wide association analysis identifies TXNRD2, ATXN2 and FOXC1 as susceptibility loci for primary open-angle glaucoma</article-title><source>Nat Genet</source><year>2016</year><volume>48</volume><fpage>189</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">26752265</pub-id>
</element-citation></ref><ref id="R91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Blanc</surname><given-names>RS</given-names></name>
<name><surname>Richard</surname><given-names>S</given-names></name></person-group><article-title>Arginine methylation: The coming of age</article-title><source>Mol Cell</source><year>2017</year><volume>65</volume><fpage>8</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">28061334</pub-id>
</element-citation></ref><ref id="R92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tradewell</surname><given-names>ML</given-names></name>
<name><surname>Yu</surname><given-names>Z</given-names></name>
<name><surname>Tibshirani</surname><given-names>M</given-names></name>
<name><surname>Boulanger</surname><given-names>MC</given-names></name>
<name><surname>Durham</surname><given-names>HD</given-names></name>
<name><surname>Richard</surname><given-names>S</given-names></name></person-group><article-title>Arginine methylation by PRMT1 regulates nuclear-cytoplasmic localization and toxicity of FUS/TLS harbouring ALS-linked mutations</article-title><source>Hum Mol Genet</source><year>2012</year><volume>21</volume><fpage>136</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">21965298</pub-id>
</element-citation></ref></ref-list></back></article>